Compounds for payload delivery

Abstract

The present disclosure relates to novel compounds, lipid compositions and lipid nanoparticles comprising such compounds and their use for encapsulation and / or delivery of various payloads into blood, cells, tissues and / or organs.

Description

[0001] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0002] COMPOUNDS FOR PAYLOAD DELIVERY FIELD

[0003] [1] The present disclosure relates to novel compounds, lipid compositions and lipid nanoparticles comprising such compounds and their use for encapsulation and / or delivery of various payloads into blood, cells, tissues and / or organs.

[0004] BACKGROUND

[0005] [2] Lipid nanoparticles (LNPs) are a key tool in modern pharmaceutical technologies. LNPs have become especially important in the field of targeting technology for therapeutic molecules such as ribonucleic acid (RNA), deoxyribonucleic acid (DNA), and other small molecules. The development of LNPs has enabled the efficient delivery of therapeutic and / or prophylactic nucleic acids for use in vaccines, gene therapy and the treatment of genetic disorders, in particular rare genetic disorders. Such nanoparticles are designed to protect their cargo from degradative enzymes and immune reactions, to keep cargo stable and to allow for the controlled release of drugs in target cells.

[0006] [3] One of the key components of LNPs is ionizable lipids. These lipids may facilitate encapsulation of nucleic acid. At a specific pH, ionizable lipids are positively charged, allowing efficient binding to negatively charged nucleic acids, such as RNA (e.g. small interfering RNA (siRNA), messenger RNA (mRNA), transfer RNA (tRNA), complementary DNA (cDNA) or guide RNA (gRNA). This interaction facilitates efficient encapsulation and also increases the stability of the resulting nanoparticle.

[0007] [4] Additionally ionizable lipids improve the cellular uptake and endosomal escape of nucleic acids after their delivery to target cells. These properties may be crucial for increasing the efficiency of pay load capable of therapeutic and / or prophylactic effects and other therapeutic molecules, leading to improved therapeutic and / or prophylactic effect. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0008] [5] Although a variety of lipids and lipid-like molecules have been reported for encapsulation and / or delivery of various payloads (e.g. RNA), there is still a need for novel compounds, lipid compositions and / or lipid nanoparticles comprising such lipids and compositions formulations for the delivery of such payloads to a tissue.

[0009] BRIEF SUMMARY

[0010] [6] The present disclosure provides novel compounds of Formula I and lipid compositions and methods of making thereof. In some aspects, the compounds of Formula I may comprise ionizable compounds. The disclosure is based in part on the discovery that the disclosed compounds of Formula I, lipid compositions and methods are useful for forming nanoparticles which may encapsulate and / or deliver various payloads into cells, tissue and / or organs. The compounds of Formula I are suitable as delivery systems for therapeutic and / or prophylactic molecules.

[0011] [7] In some aspects, the disclosure relates to a compound of Formula I:

[0012]

[0013] wherein

[0014] A1is -CH2- or a direct bond;

[0015] A2is -CH2- or a direct bond;

[0016] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle comprising at least 2 nitrogen DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0017] atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, -OC(=O)O-, and -CH(OH)-

[0018] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12alkylene chains, C4-C12alkenylene chains, C4-C12alkynylene chains and C8-C12arylene comprising chains, wherein in said C2-C12alkylene chain, one or more -CH2- groups may be replaced with one or more O, S or -N(R6)-;

[0019] wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4;

[0020] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -Se- S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, -CH3 group may be replaced with - OH, -CH2F, -CHF2or -CF3;

[0021] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -Se- S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2or -CF3; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0022] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, - CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3;

[0023] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstitued or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3;

[0024] wherein R1comprises at least 7 carbon atoms;

[0025] wherein if R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z1;

[0026] wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2;

[0027] wherein Z1and Z2are the same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0028] -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -COO(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3,

[0029] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0030]

[0031] wherein

[0032] each R5is the same or different from each other, and is hydrogen or -CH3;

[0033] each E is same or different from each other, wherein each E is O and S;

[0034] n is an integer within the range of 1 to 5; and

[0035] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group comprising of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2- N+(CH3)3, -O(C1-C3alkyl), -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, o

[0036]

[0037] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0038]

[0039] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0040] wherein R5, E and n are as defined above;

[0041] or pharmaceutically acceptable salts or solvates thereof.

[0042] [8] The following paragraphs provide additional aspects of the compounds of Formula I.

[0043] [9] In some aspects, the disclosure relates to compounds of Formula I in which

[0044] A1is -CH2- or a direct bond;

[0045] A2is -CH2- or a direct bond;

[0046] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle comprising at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;

[0047] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains or C4-C12 alkenylene chains or C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2- groups may optionally be replaced with one or more O and / or S atoms and / or -N(R6)-;

[0048] wherein R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4;

[0049] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, - NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-, and -S-, wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, the terminal -CH3 group may optionally be replaced with -OH, -CH2F, -CHF2or -CF3; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0050] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-,-O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, the terminal CH3 group may optionally be replaced with -OH, -CH2F-, -CHF2 or -CF3;

[0051] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, the terminal -CH3 group may optionally be replaced with -OH, -CH2F-, -CHF2 or -CF3;

[0052] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-,-O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, the terminal -CH3 group may optionally be replaced with -OH, -CH2F-, -CHF2 or -CF3; wherein R1comprises at least 7 carbon atoms;

[0053] and wherein if R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z1; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0054] and wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2;

[0055] Z1and Z2are same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, C(=O)N[(CH2)2OH]2,

[0056] --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2- N+(CH3)3,

[0057] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0058]

[0059] wherein

[0060] each R5are same or different from each other, wherein each R5is selected from hydrogen and - CH3;

[0061] each E are same or different from each other, wherein each E is selected from O and S atoms; n is an integer within the range of 1 to 5; and

[0062] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -CONHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-COO, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0063]

[0064] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0065]

[0066] , and

[0067] wherein R5, E and n are as defined above;

[0068] or pharmaceutically acceptable salts or solvates thereof.

[0069]

[0010] In some aspects, the disclosure relates to compounds of Formula I in which

[0070] A1is -CH2- or a direct bond;

[0071] A2is -CH2- or a direct bond;

[0072] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle comprising at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;

[0073] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains or C4-C12 alkenylene chains or C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2- groups are optionally replaced with one or more O and / or S atoms and / or -N(R6)-;

[0074] wherein R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0075] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-, and -S-, wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2or -CF3;

[0076] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, - CHF2or -CF3;

[0077] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, - CHF2or -CF3;

[0078] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se- DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0079] , -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3group is optionally replaced with -OH, -CH2F, - CHF2or -CF3;

[0080] wherein R1comprises at least 7 carbon atoms;

[0081] and wherein if R3is C1-C4 alkyl then one hydrogen from the terminal -CH3group is optionally substituted with Z1;

[0082] and wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3group is optionally substituted with Z2;

[0083] Z1and Z2are same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, C(=O)N[(CH2)2OH]2,

[0084] --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3-, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2- N+(CH3)3,

[0085] -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,

[0086]

[0087] , and

[0088] wherein

[0089] each R5are same or different from each other, wherein each R5is selected from hydrogen and - CH3;

[0090] each E are same or different from each other, wherein each E is selected from O and S atoms; n is an integer within the range of 1 to 5; and

[0091] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, F, -C(=O)O(C1-C3alkyl), DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0092] -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -CONHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-COO, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0093]

[0094] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0095]

[0096] wherein R5, E and n are as defined above;

[0097] or pharmaceutically acceptable salts or solvates thereof.

[0098]

[0011] In some aspects, the disclosure relates to compounds of Formula I in which

[0099] A1is -CH2- or a direct bond;

[0100] A2is -CH2- or a direct bond;

[0101] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0102] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains, C4-C12 alkenylene chains, C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in said C2-C12 alkylene chain, one or more -CH2- groups may be replaced with one or more O, S or -N(R6)-;

[0103] wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4;

[0104] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0105] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0106] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0107] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0108] -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0109] wherein R1comprises at least 7 carbon atoms;

[0110] wherein if R3is C1-C4alkyl then one hydrogen from the terminal -CH3group may be substituted with Z1;

[0111] wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2;

[0112] wherein Z1and Z2are the same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -COO(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3,

[0113] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0114]

[0115] , and

[0116] wherein

[0117] each R5is the same or different from each other, and is hydrogen or -CH3;

[0118] each E is same or different from each other, wherein each E is O and S;

[0119] n is an integer within the range of 1 to 5; and

[0120] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group comprising of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0121] -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0122]

[0123] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0124]

[0125] , and

[0126] wherein R5, E and n are as defined above;

[0127] or pharmaceutically acceptable salts or solvates thereof.

[0128]

[0012] In some aspects, the disclosure relates to compounds of Formula I in which

[0129] A1is -CH2- or a direct bond;

[0130] A2is -CH2- or a direct bond;

[0131] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0132] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains, C4-C12 alkenylene chains, C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in said C2-C12 alkylene chain, one or more -CH2- groups may optionally be replaced with one or more O and / or S and / or -N(R6)-;

[0133] wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4;

[0134] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-;

[0135] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in the said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-;

[0136] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in the said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-;

[0137] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in the said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0138] -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-;

[0139] wherein R1comprises at least 7 carbon atoms;

[0140] and wherein if R1or R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z1;

[0141] and wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2;

[0142] Z1and Z2are same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3,

[0143] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0144]

[0145] wherein

[0146] each R5is same or different from each other, wherein each R5is hydrogen or -CH3;

[0147] each E is same or different from each other, wherein each E is O or S;

[0148] n is an integer within the range of 1 to 5; and

[0149] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0150] -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -CONH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0151]

[0152] -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-COO,

[0153]

[0154] wherein R5, E and n are as defined above;

[0155] or pharmaceutically acceptable salts or solvates thereof.

[0156]

[0013] In some aspects, the disclosure relates to compounds of Formula I in which

[0157] A1is -CH2- or a direct bond;

[0158] A2is -CH2- or a direct bond;

[0159] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0160] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains, C4-C12 alkenylene chains, C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in said C2-C12 alkylene chain, one or more -CH2- groups are optionally replaced with one or more O, S and / or -N(R6)-; wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4;

[0161] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH-groups are optionally replaced with > C(OH)-;

[0162] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)-;

[0163] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH-groups are optionally replaced with > C(OH)-;

[0164] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups are optionally replaced DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0165] with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)-;

[0166] wherein R1comprises at least 7 carbon atoms;

[0167] wherein if R1or R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z1;

[0168] wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group are substituted with Z2;

[0169] Z1and Z2are the same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -CONH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3,

[0170] -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-COO,

[0171]

[0172] wherein

[0173] each R5is same or different from each other, wherein each R5is hydrogen or -CH3;

[0174] each E is same or different from each other, wherein each E is O or S;

[0175] n is an integer within the range of 1 to 5; and DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0176] T1and T2are the same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -CON[(CH2)2OH]2, -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -CONHCH[C(=O)NH2]2, -CONH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0177]

[0178] wherein R5, E and n are as defined above;

[0179] or pharmaceutically acceptable salts or solvates thereof.

[0180]

[0014] In some aspects, the disclosure relates to compounds of Formula I in which

[0181] A1is -CH2- or a direct bond;

[0182] A2is -CH2- or a direct bond;

[0183] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0184] -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=0)-, -NHC(=S)NH-, and -CH(OH)-;

[0185] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C18 alkylene chains or C4-C18 alkenylene chains or C4-C18 alkynylene chains and C8-C18 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2-groups may optionally be replaced with one or more O and / or S and / or -N(R6)-;

[0186] wherein R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4;

[0187] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0188] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0189] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0190] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0191] wherein R1comprises at least 7 carbon atoms;

[0192] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0193]

[0194] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0195]

[0196] , and

[0197] wherein

[0198] each R5is same or different from each other, wherein each R5is hydrogen or -CH3;

[0199] each E is same or different from each other, wherein each E is O or S;

[0200] n is an integer within the range of 1 to 5; and

[0201] or pharmaceutically acceptable salts or solvates thereof.

[0202]

[0015] In some aspects, the disclosure relates to compounds of Formula I in which

[0203] A1is -CH2- or a direct bond; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0204] A2is -CH2- or a direct bond;

[0205] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five- membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-;

[0206] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C18 alkylene chains or C4-C18 alkenylene chains or C4-C18 alkynylene chains and C8-C18 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2-groups may be replaced with one or more O and / or S and / or -N(R6)-;

[0207] wherein R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4;

[0208] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0209] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0210] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0211] -OC(=O)-, -C(=0)0-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0212] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0213] wherein R1comprises at least 7 carbon atoms;

[0214] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0215]

[0216] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0217]

[0218] wherein

[0219] each R5is same or different from each other, wherein each R5is hydrogen or -CH3; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0220] each E is same or different from each other, wherein each E is O or S;

[0221] n is an integer within the range of 1 to 5; and

[0222] or pharmaceutically acceptable salts or solvates thereof.

[0223]

[0016] In some aspects, the disclosure relates to compounds of Formula I in which

[0224] A1is -CH2- or a direct bond;

[0225] A2is -CH2- or a direct bond;

[0226] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-;

[0227] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C18 alkylene chains or C4-C18 alkenylene chains or C4-C18 alkynylene chains and C8-C18 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2-groups may optionally be replaced with one or more O and / or S;

[0228] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0229] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0230] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0231] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0232] wherein R1comprises at least 7 carbon atoms;

[0233] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NIL, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0234]

[0235] -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,

[0236]

[0237] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0238] wherein

[0239] each R5is same or different from each other, wherein each R5is hydrogen or -CH3;

[0240] each E is same or different from each other, wherein each E is O or S;

[0241] n is an integer within the range of 1 to 5; and

[0242] or pharmaceutically acceptable salts or solvates thereof.

[0243]

[0017] In some aspects, the disclosure relates to compounds of Formula I in which

[0244] A1is -CH2- or a direct bond;

[0245] A2is -CH2- or a direct bond;

[0246] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five- membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-;

[0247] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C18 alkylene chains or C4-C18 alkenylene chains or C4-C18 alkynylene chains and C8-C18 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2-groups may be replaced with one or more O and / or S;

[0248] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0249] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0250] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0251] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from -CH(OH)- -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0252] wherein R1comprises at least 7 carbon atoms;

[0253] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0254]

[0255] wherein

[0256] each R5is same or different from each other, wherein each R5is hydrogen or -CH3;

[0257] each E is same or different from each other, wherein each E is O or S;

[0258] n is an integer within the range of 1 to 5; and

[0259] or pharmaceutically acceptable salts or solvates thereof.

[0260]

[0018] In some aspects, the disclosure relates to compounds of Formula I in which

[0261] A1is -CH2- or a direct bond;

[0262] A2is -CH2- or a direct bond;

[0263] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, - C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0264] Y1is -(CH2)D1U1(CH2)D2U2(CH2)D3-;

[0265] wherein DI is an integer ranging from 1 to 10;

[0266] wherein D2 is an integer ranging from 1 to 10;

[0267] wherein D3 is an integer ranging from 1 to 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025 wherein U1is selected from the group consisting of single bond, double bond, triple bond, -O-

[0268]

[0269] , -S-, -S-S-, and

[0270] wherein U2 is selected from the group consisting of single bond, double bond, triple bond, -O-

[0271]

[0272] , -S-, -S-S-, and;

[0273] Y2is -(CH2)D4U3(CH2)D5U4(CH2)D6-;

[0274] wherein D4 is an integer ranging from 1 to 10;

[0275] wherein D5 is an integer ranging from 1 to 10;

[0276] wherein D6 is an integer ranging from 1 to 10;

[0277] wherein U3 is selected from the group consisting of single bond, double bond, triple bond,

[0278]

[0279] -O-, -S-, -S-S-, and;

[0280] wherein U4 is selected from the group consisting of a single bond, double bond, triple bond,

[0281]

[0282] -O-, -S-, -S-S-, and DTS Ref.: 41089.BTL.P110PC December 19, 2025 wherein Y1has 2 to 18 carbons and wherein Y2has 2 to 18 carbons;

[0283] R1is -(CH2)E1V1(CH2)E2V2(CH2)E3;

[0284] wherein El is an integer ranging from 1 to 10;

[0285] wherein E2 is an integer ranging from 1 to 10;

[0286] wherein E3 is an integer ranging from 1 to 10;

[0287] wherein V1is selected from the group consisting of single bond, double bond, triple bond,

[0288]

[0289] -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0290] wherein V2is selected from the group consisting of single bond, double bond, triple bond,

[0291]

[0292] -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0293] R2IS -(CH2)E4V3(CH2)E5V4(CH2)E6;

[0294] wherein E4 is an integer ranging from 1 to 10;

[0295] wherein E5 is an integer ranging from 1 to 10;

[0296] wherein E6 is an integer ranging from 1 to 10;

[0297] wherein V3 is selected from the group consisting of single bond, double bond, triple bond,

[0298]

[0299] CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and DTS Ref.: 41089.BTL.P110PC December 19, 2025 wherein V4 is selected from the group consisting of single bond, double bond, triple bond,

[0300]

[0301] CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0302] R3is -(CH2)E7V5(CH2)E8V6(CH2)E9;

[0303] wherein E7 is an integer ranging from 1 to 10;

[0304] wherein E8 is an integer ranging from 1 to 10;

[0305] wherein E9 is an integer ranging from 1 to 10;

[0306] wherein V5is selected from the group consisting of single bond, double bond, triple bond,

[0307]

[0308] CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0309] wherein V6 is selected from the group consisting of single bond, double bond, triple bond,

[0310]

[0311] -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0312] R4is -(CH2)E10V7(CH2)E11V8(CH2)E12;

[0313] wherein E10 is an integer ranging from 1 to 10;

[0314] wherein El 1 is an integer ranging from 1 to 10;

[0315] wherein E12 is an integer ranging from 1 to 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0316] wherein V7is selected from the group consisting of single bond, double bond, triple bond,

[0317]

[0318] CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0319] wherein V8 is selected from the group consisting of single bond, double bond, triple bond,

[0320]

[0321] CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, -S-, and

[0322] wherein R1comprises at least 7 carbon atoms;

[0323] T1and T2are the same or different from each other, wherein T1and T2are independently selected

[0324]

[0325] from the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0326]

[0327] or pharmaceutically acceptable salts or solvates thereof.

[0328]

[0019] In some aspects, the disclosure relates to compounds of Formula I in which

[0329] A1is -CH2- or a direct bond;

[0330] A2is -CH2- or a direct bond;

[0331] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0332] -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0333] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0334] ■

[0335]

[0336] the group consisting of C2-C8 alkylene chains,

[0337] -CH2-CH2-S-S-CH2-CH2- and -CH2-CH2-O-CH2-CH2-;

[0338] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0339] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0340] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0341] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0342] wherein R1comprises at least 8 carbon atoms; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0343] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0344]

[0345] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0346]

[0347] or pharmaceutically acceptable salts or solvates thereof.

[0348]

[0020] In some aspects, the disclosure relates to compounds of Formula I in which

[0349] A1is -CH2- or a direct bond;

[0350] A2is -CH2- or a direct bond;

[0351] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0352] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0353]

[0354] the group consisting of C2-C8 alkylene chains,

[0355] -CH2-CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0356] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0357] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more groups DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0358] selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0359] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0360] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0361] wherein R1comprises at least 8 carbon atoms;

[0362] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0363] 0

[0364]

[0365] \ N • I --y

[0366] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0367] / ( ) L I

[0368]

[0369] 0

[0370] or pharmaceutically acceptable salts or solvates thereof.

[0371]

[0021] In some aspects, the disclosure relates to compounds of Formula I in which

[0372] A1is -CH2- or a direct bond;

[0373] A2is -CH2- or a direct bond;

[0374] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0375] -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, - C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0376] Y1is -(CH2)D1U1(CH2)D2-;

[0377] wherein D1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0378] wherein D2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0379] wherein U1is selected from the group consisting of single bond, double bond, triple bond,

[0380]

[0381] Y2is - (CH2)D3U2(CH2)D4-;

[0382] wherein D3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0383] wherein D4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0384] wherein U2is selected from the group consisting of single bond, double bond, triple bond,

[0385] I

[0386]

[0387] ....

[0388] -O-, -S-, -S-S-, and;

[0389] wherein Y1has 2 to 12 carbons and wherein Y2has 2 to 12 carbon,;

[0390] R1is -(CH2)EIVI(CH2)E2V2(CH2)E3;

[0391] wherein E1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0392] wherein E2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0393] wherein E3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0394]

[0395] wherein Vi is selected from the group consisting of single bond,

[0396] -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0397]

[0398] wherein V2 is selected from the group consisting of single bond,, -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0399] R2IS -(CH2)E4V3(CH2)E5V4(CH2)E6;

[0400] wherein E4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0401] wherein E5 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0402] wherein E6 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0403]

[0404] wherein V3 is selected from the group consisting of single bond,, -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0405]

[0406] wherein V4 is selected from the group consisting of single bond,, -CH(OH)-, -OC(=O)- and -C(=O)O-;

[0407] R3is -(CH2)E7V5(CH2)E8V6(CH2)E9;

[0408] wherein E7 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0409] wherein E8 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025 wherein E9 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0410]

[0411] wherein V8 is selected from the group consisting of single bond,, -CH(OH)-, - OC(=O)- and -C(=O)O-;

[0412]

[0413] wherein V6 is selected from the group consisting of single bond,, -CH(OH)-, - OC(=O)- and -C(=O)O-;

[0414] R4is -(CH2)E10V7(CH2)E11V8(CH2)E12;

[0415] wherein E10 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0416] wherein Ell is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0417] wherein E12 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0418]

[0419] wherein V7 is selected from the group consisting of single bond,, -CH(OH)-, - OC(=O)- and -C(=O)O-;

[0420]

[0421] wherein V8 is selected from the group consisting of single bond,, -CH(OH)-, - OC(=O)- and -C(=O)O-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0422] wherein R1comprises at least 7 carbon atoms;

[0423] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0424]

[0425] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0426]

[0427] or pharmaceutically acceptable salts or solvates thereof.

[0428]

[0022] In some aspects, the disclosure relates to compounds of Formula I in which

[0429] A1is -CH2- or a direct bond;

[0430] A2is -CH2- or a direct bond;

[0431] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0432] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0433] 1 / the group consisting of C2-C6 alkylene chains,

[0434] -CH2-CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0435] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0436] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0437] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0438] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0439] wherein R1comprises at least 8 carbon atoms;

[0440] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0441]

[0442] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0443]

[0444] or pharmaceutically acceptable salts thereof.

[0445]

[0023] In some aspects, the disclosure relates to compounds of Formula I in which

[0446] A1is -CH2- or a direct bond;

[0447] A2is -CH2- or a direct bond;

[0448] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0449] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0450] VI

[0451] the group consisting of C2-C6 alkylene chains,

[0452] -CH2-CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0453] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0454] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0455] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0456] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0457] wherein R1comprises at least 8 carbon atoms;

[0458] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0459]

[0460] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0461]

[0462] or pharmaceutically acceptable salts thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0463]

[0024] In some aspects, the disclosure relates to compounds of Formula I in which

[0464] A1is -CH2- or a direct bond;

[0465] A2is -CH2- or a direct bond;

[0466] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)NHNH-, -CH2-, -O-, -NH-, -NHC(=O)-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -N=CH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -C(=O)-, and -CH(OH)-;

[0467] Y1is -(CH2)DIUI(CH2)D2-;

[0468] wherein DI is 1, 2, 3, 4, or 5;

[0469] wherein D2 is 1, 2, 3, 4, or 5;

[0470] wherein Ui is selected from the group consisting of single bond, -O-, -S-S-, and

[0471]

[0472] Y2is - (CH2)D3U2(CH2)D4-;

[0473] wherein D3 is 1, 2, 3, 4, or 5;

[0474] wherein D4 is 1, 2, 3, 4, or 5;

[0475]

[0476] wherein U2 is selected from the group consisting of bond, -O-, -S-S-, and

[0477] wherein Y1has 2 to 6 carbons and wherein Y2has 2 to 6 carbon,; DTS Ref.: 41089.BTL.P110PC December 19, 2025 R1is -(CH2)E1V1(CH2)E2V2(CH2)E3;

[0478] wherein E1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0479] wherein E2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0480] wherein E3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0481]

[0482] wherein Vi is selected from the group consisting of single bond,

[0483]

[0484] -C(=O)O-;

[0485]

[0486] wherein V2 is selected from the group consisting of single bond,

[0487]

[0488] C(=O)O-;

[0489] R2is -(CH2)E4V3(CH2)E5V4(CH2)E6;

[0490] wherein E4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0491] wherein E5 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0492] wherein E6 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0493]

[0494] wherein V3 is selected from the group consisting of single bond,, and C(=O)O-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0495]

[0496] wherein V4 is selected from the group consisting of single bond,

[0497]

[0498] -C(=O)O-;

[0499] R3is -(CH2)E7V5(CH2)E8V6(CH2)E9;

[0500] wherein E7 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0501] wherein E8 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0502] wherein E9 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0503]

[0504] wherein V8 is selected from the group consisting of single bond,, and C(=O)O-;

[0505]

[0506] wherein V6 is selected from the group consisting of single bond,, and -C(=O)O-;

[0507] R4is -(CH2)E10V7(CH2)E11V8(CH2)E12;

[0508] wherein E10 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0509] wherein Ell is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0510] wherein E12 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0511]

[0512] wherein V7 is selected from the group consisting of single bond,

[0513]

[0514] C(=O)O-;

[0515]

[0516] wherein V8 is selected from the group consisting of single bond,, and C(=O)O-;

[0517] wherein R1comprises at least 7 carbon atoms;

[0518] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0519]

[0520] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0521]

[0522] or pharmaceutically acceptable salts or solvates thereof.

[0523]

[0025] In some aspects, the disclosure relates to compounds of Formula I in which

[0524] A1is -CH2- or a direct bond;

[0525] A2is -CH2- or a direct bond;

[0526] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)- and -C(=S)NH-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0527] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0528]

[0529] the group consisting of C2-C6 alkylene chains,, -CH2- CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0530] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0531] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0532] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0533] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0534] wherein R1comprises at least 8 carbon atoms;

[0535] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0536]

[0537] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0538]

[0539] or pharmaceutically acceptable salts or solvates thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0540]

[0026] In some aspects, the disclosure relates to compounds of Formula I in which

[0541] A1is -CH2- or a direct bond;

[0542] A2is -CH2- or a direct bond;

[0543] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)- and -C(=S)NH-;

[0544] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0545]

[0546] the group consisting of C2-C6 alkylene chains, -CH2- CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0547] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0548] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0549] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0550] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may be replaced with one or more -C(=O)O-groups;

[0551] wherein R1comprises at least 8 carbon atoms; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0552] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0553]

[0554] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0555]

[0556] or pharmaceutically acceptable salts or solvates thereof.

[0557]

[0027] In some aspects, the disclosure relates to compounds of Formula I in which

[0558] A1is -CH2- or a direct bond;

[0559] A2is -CH2- or a direct bond;

[0560] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)- and -C(=S)NH-;

[0561] Y1is -(CH2)DIUI(CH2)D2-;

[0562] wherein DI is 1, 2, 3, 4, or 5;

[0563] wherein D2 is 1, 2, 3, 4, or 5;

[0564] wherein Ui is selected from the group consisting of single bond, -O-, -S-S-, and

[0565] / ' "r " KT \

[0566]

[0567] Y2is -(CH2)D3U2(CH2)D4-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0568] wherein D3 is 1, 2, 3, 4, or 5;

[0569] wherein D4 is 1, 2, 3, 4, or 5;

[0570]

[0571] wherein U2 is selected from the group consisting of bond, -O-, -S-S-, and

[0572] wherein Y1has 2 to 6 carbons and wherein Y2has 2 to 6 carbon;

[0573] R1is -(CH2)E1V1(CH2)E2V2(CH2)E3;

[0574] wherein E1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0575] wherein E2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0576] wherein E3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0577]

[0578] wherein Vi is selected from the group consisting of single bond,, and C(=O)O-;

[0579]

[0580] wherein V2 is selected from the group consisting of single bond,, and C(=O)O-;

[0581] R2is -(CH2)E4V3(CH2)E5V4(CH2)E6;

[0582] wherein E4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0583] wherein E5 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025 wherein E6 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0584]

[0585] wherein V3 is selected from the group consisting of single bond,, and C(=O)O-;

[0586]

[0587] wherein V4 is selected from the group consisting of single bond,, and -C(=O)O-;

[0588] R3is - (CH2)E7V5(CH2)E8V6(CH2)E9;

[0589] wherein E7 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0590] wherein E8 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0591] wherein E9 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0592]

[0593] wherein V5 is selected from the group consisting of single bond,

[0594]

[0595] C(=O)O-;

[0596]

[0597] wherein V6 is selected from the group consisting of single bond,

[0598]

[0599] -C(=O)O-;

[0600] R4is - (CH2)E10V7(CH2)E11V8(CH2)E12;

[0601] wherein E10 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0602] wherein Ell is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0603] wherein E12 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0604]

[0605] wherein V7 is selected from the group consisting of single bond,

[0606]

[0607] C(=O)O-;

[0608]

[0609] wherein V8 is selected from the group consisting of single bond,, and -C(=O)O-;

[0610] wherein R1comprises at least 7 carbon atoms;

[0611] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0612]

[0613] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0614]

[0615] or pharmaceutically acceptable salts or solvates thereof.

[0616]

[0028] In some aspects, the disclosure relates to compounds of Formula I in which

[0617] A1is -CH2- or a direct bond;

[0618] A2is -CH2- or a direct bond;

[0619] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH- and -NHC(=O)-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0620] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C4-C8 alkylene chains;

[0621] R1is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0622] R2is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0623] R3is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0624] R4is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0625] T1is -CN;

[0626] T2is -H;

[0627] or pharmaceutically acceptable salts or solvates thereof.

[0628]

[0029] In some aspects, the disclosure relates to compounds of Formula I in which

[0629] A1is -CH2- or a direct bond;

[0630] A2is -CH2- or a direct bond;

[0631] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH- and -NHC(=O)-;

[0632] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C4-C8 alkylene chains;

[0633] R1is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0634] R2is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0635] R3is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0636] R4is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0637] T1is -H;

[0638] T2is -H; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0639] or pharmaceutically acceptable salts or solvates thereof.

[0640]

[0030] In some aspects, the disclosure relates to compounds of Formula I in which

[0641] A1is -CH2- or a direct bond;

[0642] A2is -CH2- or a direct bond;

[0643] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH- and -NHC(=O)-;

[0644] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of -CH2-O-CH2-, -CH2-O-CH2-CH2-, -CH2-CH2-O-CH2-, -CH2-CH2- O-CH2-CH2-, -CH2-O-CH2-CH2-CH2-, and -CH2-CH2-CH2-O-CH2-;

[0645] R1is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0646] R2is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0647] R3is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0648] R4is selected from the group consisting of C10-C14 alkyl, wherein said C10-C14 alkyl is linear;

[0649] T1is -H;

[0650]

[0651] or pharmaceutically acceptable salts or solvates thereof.

[0652]

[0031] In some aspects, the disclosure relates to compounds of Formula I in which

[0653] A1is -CH2- or a direct bond;

[0654] A2is -CH2- or a direct bond; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0655] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=O)NHNH- -NHC(=O)-, -C(=S)NH-, -

[0656] O

[0657]

[0658] C(=O)NH-, -NHC(=O)O-, -NHC(=O)NH- and

[0659] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0660]

[0661] the group consisting of C2-C6 alkylene chains, -CH2- CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0662] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- or -CH(OH)- groups;

[0663] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- or -CH(OH)- groups;

[0664] R3is selected from the group consisting of C1-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in said alkyl, terminal CH3group may optionally be replaced with -OH;

[0665] R4is selected from the group consisting of C1-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in said alkyl, terminal CH3group may optionally be replaced with -OH;

[0666] wherein R1comprises at least 8 carbon atoms; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0667] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0668]

[0669] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0670]

[0671] or pharmaceutically acceptable salts or solvates thereof.

[0672]

[0032] In some aspects, the disclosure relates to compounds of Formula I in which

[0673] A1is -CH2- or a direct bond;

[0674] A2is -CH2- or a direct bond;

[0675] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)- and -C(=S)NH-;

[0676] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0677]

[0678] the group consisting of C2-C6 alkylene chains, -CH2- CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0679] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups;

[0680] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0681] R3is selected from the group consisting of C1-C16alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in said alkyl, terminal CH3group is optionally replaced with -OH;

[0682] R4is selected from the group consisting of C1-C16 alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in said alkyl, terminal CH3 group is optionally replaced with -OH;

[0683] wherein R1comprises at least 8 carbon atoms;

[0684] T1and T2are same or different from each other, wherein T1and T2are independently selected from O

[0685]

[0686] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0687] / .0.

[0688]

[0689]

[0690] or pharmaceutically acceptable salts or solvates thereof.

[0691]

[0033] In some aspects, the R1, R2, R3and / or R4is selected from the groups of the following list: DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0692]

[0693]

[0034] In some aspects, the R1, R2, R3and / or R4is selected from the groups of the following list: DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0694]

[0695]

[0035] In some aspects, subset of compounds of Formula I may include compounds of Formula II: DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0696]

[0697] wherein

[0698] A1is -CH2- or a direct bond;

[0699] A2is -CH2- or a direct bond;

[0700] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;

[0701] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group comprising of C2-C12 alkylene chains or C4-C12 alkenylene chains or C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2- groups may optionally be replaced with one or more O and / or S;

[0702] RAis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched;

[0703] Rcis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0704] REis selected from the group consisting of C5-C6alkylene chain, wherein said alkylene chain is linear or branched;

[0705] RGis selected from the group consisting of C5-C6alkylene chain, wherein said alkylene chain is linear or branched;

[0706] RBis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0707] RDis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0708] RFis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0709] RHis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0710] B1is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0711] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0712] B2is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0713] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0714] B3is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0715] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0716] B4is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0717] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0718] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of hydrogen, -C(=O)NH2, -CN, -F,

[0719]

[0720] or pharmaceutically acceptable salts or solvates thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0721]

[0036] In some aspects, subset of compounds of Formula I may include compounds of Formula II in which:

[0722] A1is -CH2- or a direct bond;

[0723] A2is -CH2- or a direct bond;

[0724] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle consisting of at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;

[0725] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group comprising of C2-C12 alkylene chains or C4-C12 alkenylene chains or C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2- groups may be replaced with one or more O and / or S;

[0726] RAis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched;

[0727] Rcis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched;

[0728] REis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched;

[0729] RGis selected from the group consisting of C5-C6 alkylene chain, wherein said alkylene chain is linear or branched;

[0730] RBis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0731] RDis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0732] RFis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0733] RHis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0734] B1is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0735] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0736] B2is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0737] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0738] B3is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0739] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0740] B4is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-,

[0741] -S-S-. -O-(C=O)-O- and -CH(OH)-;

[0742] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of hydrogen, -C(=O)NH2, -CN, -F,

[0743]

[0744] or pharmaceutically acceptable salts or solvates thereof.

[0745]

[0037] In some aspects, compound of a subset of compounds of Formula II includes those in which

[0746] A1is -CH2- or a direct bond;

[0747] A2is -CH2- or a direct bond;

[0748] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle consisting of at least 2 nitrogen DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0749] atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;

[0750] Y1is -(CH2)D1U1(CH2)D2-;

[0751] wherein DI is 1, 2, 3, 4, or 5;

[0752] wherein D2 is 1, 2, 3, 4, or 5;

[0753] wherein Ui is selected from the group consisting of single bond, -O-, -S-S-, and

[0754]

[0755] Y2is -(CH2)D3U2(CH2)D4-;

[0756] wherein D3 is 1, 2, 3, 4, or 5;

[0757] wherein D4 is 1, 2, 3, 4, or 5;

[0758]

[0759] wherein U2 is selected from the group consisting of bond, -O-, -S-S-, and

[0760] wherein Y1has 2 to 12 carbons and wherein Y2has 2 to 12 carbon;

[0761] RAis selected from the group consisting of C5-C6alkyl, wherein said alkyl is linear or branched;

[0762] Rcis selected from the group consisting of C5-C6alkyl, wherein said alkyl is linear or branched;

[0763] REis selected from the group consisting of C5-C6alkyl, wherein said alkyl is linear or branched; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0764] RGis selected from the group consisting of C5-C6alkyl, wherein said alkyl is linear or branched;

[0765] RBis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0766] RDis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0767] RFis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0768] RHis selected from the group consisting of C2-C9 alkyl, wherein said alkyl is linear or branched;

[0769] B1is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-, -S-S-,

[0770] -O-(C=O)-O- and -CH(OH);

[0771] B2is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-, -S-S-,

[0772] -O-(C=O)-O- and -CH(OH);

[0773] B3is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-, -S-S-,

[0774] -O-(C=O)-O- and -CH(OH);

[0775] B4is selected from the group consisting of -CH2-, -C(=O)O-, -O-C(=O)-, -CH=CH-, -S-S-,

[0776] -O-(C=O)-O- and -CH(OH);

[0777] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of hydrogen, -C(=O)NH2, -CN, -F; and

[0778]

[0779] or pharmaceutically acceptable salts or solvates thereof.

[0780]

[0038] In some aspects, subset of compounds of Formula I may include compounds of Formula III: DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0781]

[0782] wherein

[0783] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, -CH2C(=S)NH- and -CH(OH)-;

[0784] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12alkylene chains, C4-C12alkenylene chains, C4-C12alkynylene chains and C8-C12arylene comprising chains, wherein in said C2-C12alkylene chain, one or more -CH2- groups may optionally be replaced with one or more O, S or -N(R6)-;

[0785] wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4;

[0786] R1is selected from the group consisting of C1-C46alkyl, C2-C46alkenyl and C2-C46alkynyl, wherein said C1-C46alkyl, C2-C46alkenyl and C2-C46alkynyl may be linear or branched, and wherein in said DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0787] alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0788] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0789] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0790] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0791] wherein R1comprises at least 7 carbon atoms;

[0792] wherein if R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z1;

[0793] wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0794] wherein Z1and Z2are the same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2,

[0795] -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -COO(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3, -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,

[0796]

[0797] wherein

[0798] each R5is the same or different from each other, and is hydrogen or -CH3;

[0799] each E is same or different from each other, wherein each E is O and S;

[0800] n is an integer within the range of 1 to 5; and

[0801] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group comprising of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3-, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0802]

[0803] wherein R5, E and n are as defined above;

[0804] or pharmaceutically acceptable salts or solvates thereof.

[0805]

[0039] In some aspects, subset of compounds of Formula I may include compounds of Formula III in which:

[0806] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, - CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, -CH2C(=S)NH- and -CH(OH)-;

[0807] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12alkylene chains, C4-C12alkenylene chains, C4-C12alkynylene chains and C8-C12arylene comprising chains, wherein in said C2-C12alkylene chain, one or more -CH2- groups may be replaced with one or more O, S or -N(R6)-;

[0808] wherein each R6is the same or different from each other, wherein each R6is alkyl C1-C4; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0809] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0810] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0811] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0812] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-,-O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-;

[0813] wherein R1comprises at least 7 carbon atoms;

[0814] wherein if R3is C1-C4alkyl then one hydrogen from the terminal -CH3group may be substituted with Z1; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0815] wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group may be substituted with Z2;

[0816] wherein Z1and Z2are the same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3-, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3-, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -COO(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3,

[0817] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0818]

[0819] wherein

[0820] each R5is the same or different from each other, and is hydrogen or -CH3;

[0821] each E is same or different from each other, wherein each E is O and S;

[0822] n is an integer within the range of 1 to 5; and

[0823] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group comprising of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3-, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O-, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0824] -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,

[0825]

[0826] -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,

[0827]

[0828] and

[0829] wherein R5, E and n are as defined above;

[0830] or pharmaceutically acceptable salts or solvates thereof.

[0831]

[0040] In some aspects, subset of compounds of Formula I may include compounds of Formula III in which:

[0832] X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, -CH2C(=S)NH- and -CH(OH)-;

[0833] Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12alkylene chains, C4-C12alkenylene chains, C4-C12alkynylene chains and C8-C12arylene comprising chains, wherein in said C2-C12alkylene chain, one or more -CH2- groups may be replaced with one or more O or S;

[0834] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0835] alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0836] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0837] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0838] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-;

[0839] wherein R1comprises at least 7 carbon atoms; and

[0840] T1and T2are same or different from each other, wherein T1and T2are independently selected from the group comprising of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0841]

[0842] -N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,

[0843]

[0844] and

[0845] wherein

[0846] each R5is the same or different from each other, and is hydrogen or -CH3;

[0847] each E is same or different from each other, wherein each E is O and S;

[0848] n is an integer within the range of 1 to 5; and

[0849] or pharmaceutically acceptable salts or solvates thereof.

[0850]

[0041] In some aspects, compound of a subset of compounds of Formula III includes those in which

[0851] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)-, -CH2C(=O)NH- and -C(=S)NH-;

[0852] Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from

[0853]

[0854] the group consisting of C2-C6 alkylene chains, -CH2- CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-;

[0855] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0856] R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0857] R3is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0858] R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- groups;

[0859] wherein R1comprises at least 8 carbon atoms;

[0860] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0861]

[0862] the group consisting of -H, -CN, -F, -C(=O)NH2,, and

[0863]

[0864] or pharmaceutically acceptable salts or solvates thereof.

[0865]

[0042] In some aspects, the disclosure relates to compounds of Formula III in which

[0866] X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -NHC(=O)-, -CH2C(=O)NH- and -C(=S)NH-;

[0867] Y1is -(CH2)D1U1(CH2)D2-;

[0868] wherein DI is 1, 2, 3, 4, or 5;

[0869] wherein D2 is 1, 2, 3, 4, or 5; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0870] wherein Ui is selected from the group consisting of single bond, -O-, -S-S-, and

[0871]

[0872] Y2is -(CH2)D3U2(CH2)D4-;

[0873] wherein D3 is 1, 2, 3, 4, or 5;

[0874] wherein D4 is 1, 2, 3, 4, or 5;

[0875]

[0876] wherein U2 is selected from the group consisting of bond, -O-, -S-S-, and

[0877] wherein Y1has 2 to 6 carbons and wherein Y2has 2 to 6 carbon,;

[0878] R1is -(CH2)E1V1(CH2)E2V2(CH2)E3;

[0879] wherein E1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0880] wherein E2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0881] wherein E3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0882]

[0883] wherein Vi is selected from the group consisting of single bond,, and C(=O)O-; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0884]

[0885] wherein V2 is selected from the group consisting of single bond,

[0886]

[0887] C(=O)O-;

[0888] R2is -(CH2)E4V3(CH2)E5V4(CH2)E6;

[0889] wherein E4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0890] wherein E5 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0891] wherein E6 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0892]

[0893] wherein V3 is selected from the group consisting of single bond,, and C(=O)O-;

[0894]

[0895] wherein V4 is selected from the group consisting of single bond,, and -C(=O)O-;

[0896] R3is - (CH2)E7V5(CH2)E8V6(CH2)E9;

[0897] wherein E7 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0898] wherein E8 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0899] wherein E9 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0900]

[0901] wherein V5 is selected from the group consisting of single bond,, and C(=O)O-;

[0902]

[0903] wherein V6 is selected from the group consisting of single bond,

[0904]

[0905] -C(=O)O-;

[0906] R4is - (CH2)E10V7(CH2)E11V8(CH2)E12;

[0907] wherein E10 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0908] wherein Ell is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0909] wherein E12 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0910]

[0911] wherein V7 is selected from the group consisting of single bond,, and C(=O)O-;

[0912]

[0913] wherein V8 is selected from the group consisting of single bond,, and -C(=O)O-;

[0914] wherein R1comprises at least 7 carbon atoms; DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0915] T1and T2are same or different from each other, wherein T1and T2are independently selected from

[0916]

[0917] the group consisting of -H, -CN, -F, -C(=O)NH2, and

[0918]

[0919] or pharmaceutically acceptable salts or solvates thereof.

[0920]

[0043] Direct bond according to this application is a single bond between X1(or X2) and adamantane core.

[0921]

[0044] The compounds of Formula I, Formula II or Formula III may include one or more following aspects when applicable:

[0922]

[0045] In some aspects, both A1and A2are direct bonds.

[0923]

[0046] In some aspects, A1is -CH2- and A2is a direct bond.

[0924]

[0047] In some aspects, A2is -CH2- and A1is a direct bond.

[0925]

[0048] In some aspects, both A1and A2are -CH2-.

[0926]

[0049] In some aspects, X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, O-, and -NHC(=O)-, -C(=O)O-, -C(=S)NH-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -OC(=O)-, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -N=CH-, -CH=N-, and -CH=N-NH-.

[0927]

[0050] In some aspects, X1and X2are the same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, O-, -NHC(=O)- and -CH2C(=O)NH-.

[0928]

[0051] In some aspects, Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains and DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0929]

[0930] , wherein in the said C2-C12 alkylene chain, one or more -CH2- groups may be replaced with one or more O or S.

[0931]

[0052] In some aspects, Y1and Y2are the same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C6 alkylene chains,

[0932]

[0933] , -CH2-CH2-S-S-CH2-CH2-, and -CH2-CH2-O-CH2-CH2-.

[0934]

[0053] In some aspects, T1and T2are same or different from each other, wherein T1and T2are

[0935]

[0936] selected from the group consisting of hydrogen, -C(=O)NH2, -CN, -F, and

[0937]

[0938]

[0054] In some aspects, each of R1, R2, R3, and / or R4may comprise at least 8 carbon atoms.

[0939]

[0055] In some aspects, each of R1, R2, R3, and / or R4may comprise at least 10 carbon atoms.

[0940]

[0056] In some aspects, each of R1, R2, R3, and / or R4may comprise at least 12 carbon atoms.

[0941]

[0057] In some aspects, at least one of R1, R2, R3, and R4may comprise at least 8 carbon atoms.

[0942]

[0058] In some aspects, at least one of R1, R2, R3, and R4may comprise at least 9 carbon atoms.

[0943]

[0059] In some aspects, at least one of R1, R2, R3, and R4may comprise at least 10 carbon atoms.

[0944]

[0060] In some aspects, at least one of R1, R2, R3, and R4may comprise at least 12 carbon atoms.

[0945]

[0061] In some aspects, R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0946] branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, - C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R1may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, - C(=O)O-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S- Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0947]

[0062] In some aspects, R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, - C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R2may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, - C(=O)O-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S- Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0948]

[0063] In some aspects, R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, - C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O- DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0949] , -CF2-, -CHF-, -0-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, teminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R3may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, - C(=O)O-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S- Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0950]

[0064] In some aspects, R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups may be replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, - C(=O)O-, -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2-, -CHF-, -O-, -S- and unsubstituted or substituted carbocyclic or heterocyclic ring; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups may be replaced with > C(OH)-, and wherein in said alkyl, alkenyl or alkynyl, terminal -CH3 group may be replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R4may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, - C(=O)O-, -C(=O)NH-, -NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S- Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0951]

[0065] R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-, and -S-, wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0952] -CH2F, -CHF2 or -CF3; In other words R1may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH-, - NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0953]

[0066] R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R2may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH-, - NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0954]

[0067] R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R3may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH-, - DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0955] NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0956]

[0068] R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF- and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3; In other words R4may thus be an alkyl substituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH-, - NHC(=O)-, -OC(=O)O-, -CF2- and / or -CHF-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -Se-S-, -S-Se-, -Se-Se-, -S-S-S-, -S-Se-S-, -O- and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0957]

[0069] In some aspects, R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-; In other words R1may thus be an alkyl susbtituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH- and / or -NHC(=O)-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -O-, and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0958]

[0070] In some aspects, R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0959] groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-; In other words R2may thus be an alkyl susbtituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH- and / or -NHC(=O)-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -O-, and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0960]

[0071] In some aspects, R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-; In other words R3may thus be an alkyl susbtituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH- and / or -NHC(=O)-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -O-, and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall.

[0961]

[0072] In some aspects, R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, one or more -CH2- groups may optionally be replaced with one or more groups selected from -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said alkyl, alkenyl or alkynyl is branched, then one or more > CH- groups may optionally be replaced with > C(OH)-; In other words R4may thus be an alkyl susbtituent containing 1 to 46 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by -CH(OH)-, -OC(=O)-, -C(=O)O-, -C(=O)NH- and / or -NHC(=O)-, provided that the final substituent contains 2-46 carbon atoms overall or by -S-S-, -O-, and / or -S-, provided that the final substituent contains 1-45 carbon atoms overall. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0962]

[0073] R1is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups may optionally be replaced with one or more -C(=O)O- or -CH(OH)- groups;

[0963]

[0074] In some aspects, R1is C8-C16alkyl, wherein said C8-C16alkyl is linear or branched, and wherein in said C8-C16alkyl, one or more -CH2- groups may be replaced with one or more groups selected from -OC(=O)-. In other words R1may thus be an alkyl substituent containing 8 to 16 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by ester groups (-C(=O)O-), provided that the final substituent contains 8-16 atoms overall.

[0964]

[0075] In some aspects, R2is C8-C16alkyl, wherein said C8-C16alkyl is linear or branched, and wherein in said C8-C16alkyl, one or more -CH2- groups may be replaced with one or more groups selected from -OC(=O)-. In other words R2may thus be an alkyl substituent containing 8 to 16 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by ester groups (-C(=O)O-), provided that the final substituent contains 8-16 atoms overall.

[0965]

[0076] In some aspects, R3is C8-C16alkyl, wherein said C8-C16alkyl is linear or branched, and wherein in said C8-C16alkyl, one or more -CH2- groups may be replaced with one or more groups selected from -OC(=O)-. In other words R3may thus be an alkyl substituent containing 8 to 16 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by ester groups (-C(=O)O-), provided that the final substituent contains 8-16 atoms overall.

[0966]

[0077] In some aspects, R4is C8-C16alkyl, wherein said C8-C16alkyl is linear or branched, and wherein in said C8-C16alkyl, one or more -CH2- groups may be replaced with one or more groups selected from -C(=O)O-. In other words R4may thus be an alkyl substituent containing 8 to 16 carbon atoms in total. The chain may be linear or branched. Within this chain, one or more methylene (-CH2-) units may be replaced by ester groups (-C(=O)O-), provided that the final substituent contains 8-16 atoms overall. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0967]

[0078] In some aspects, R1comprises at least 7 carbon atoms. In some aspects, R1comprises at least 8 carbon atoms. In some aspects, R1comprises at least 10 carbon atoms. In some aspects, R1comprises at least 12 carbon atoms.

[0968]

[0079] In some aspects, R1comprises at least 8 carbon atoms. In some aspects, R1comprises at least 10 carbon atoms. In some aspects, R1comprises at least 12 carbon atoms.

[0969]

[0080] In some aspects, R1comprises at least 8 carbon atoms. In some aspects, R1preferably comprises at least 10 carbon atoms. In some aspects, R1more preferably comprises at least 12 carbon atoms.

[0970]

[0081] In some aspects, R1comprises at least 8 carbon atoms and R3comprises at least 8 carbon atoms. In some aspects, R1comprises at least 10 carbon atoms and R3comprises at least 10 carbon atoms. In some aspects, R1comprises at least 12 carbon atoms and R3comprises at least 12 carbon atoms.

[0971]

[0082] In some aspects, R1comprises at least 8 carbon atoms and R3comprises at least 8 carbon atoms. In some aspects, R1preferably comprises at least 10 carbon atoms and R3preferably comprises at least 10 carbon atoms. In some aspects, R1more preferably comprises at least 12 carbon atoms and R3more preferably comprises at least 12 carbon atoms.

[0972]

[0083] In some aspects, R1comprises at least 7 carbon atoms and R2comprises at least 7 carbon atoms. In some aspects, R1comprises at least 8 carbon atoms and R2comprises at least 8 carbon atoms. In some aspects, R1comprises at least 10 carbon atoms and R2comprises at least 10 carbon atoms. In some aspects, R1comprises at least 12 carbon atoms and R2comprises at least 12 carbon atoms.

[0973]

[0084] In some aspects, R1comprises at least 7 carbon atoms and R2comprises at least 7 carbon atoms. In some aspects, R1comprises at least 8 carbon atoms and R2comprises at least 8 carbon atoms. In some aspects, R1preferably comprises at least 10 carbon atoms and R2preferably comprises at least 10 carbon atoms. In some aspects, R1more preferably comprises at least 12 carbon atoms and R2more preferably comprises at least 12 carbon atoms.

[0974]

[0085] In some aspects, R1, and R2are identical. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0975]

[0086] In some aspects, R3and R4are identical.

[0976]

[0087] In some aspects at least two of R1, R2, R3and R4are identical.

[0977]

[0088] In some aspects, R1and R3are identical.

[0978]

[0089] In some aspects, two of R1, R2, R3and R4are different.

[0979]

[0090] In some aspects, R1, R2, R3and R4are different from each other.

[0980]

[0091] In some aspects, R1and R2are different from each other.

[0981]

[0092] In some aspects, R1and R3are different from each other.

[0982]

[0093] In some aspects, R1and R2, R3are identical.

[0983]

[0094] In some aspects, R1and R3are same and R2and R4are same, wherein R1is different from R2.

[0984]

[0095] In some aspects, R1and R2are same and R3and R4are same, wherein R1is different from R3.

[0985]

[0096] In some aspects, R1, R2, R3and R4are the same.

[0986]

[0097] In some aspects, the replacement of terminal CH3 group by -OH, CH2F, -CF3 or -CHF2 in at least one of R1, R2, R3and / or R4in a compound of Formula I may reduce pKa of said compound.

[0987]

[0098] In some aspects, R3is selected from the group consisting of C2-C16 alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2 groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in the said alkyl, terminal -CH3 is optionally replaced with -OH.

[0988]

[0099] In some aspects, at least one of R1, R2, R3or R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- groups.

[0989]

[0100] In some aspects, at least two of R1, R2, R3or R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- groups. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0990]

[0101] In some aspects, if more than one -N(R6)- is present, then R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4;

[0991]

[0102] In some aspects, disclosed alkyl, alkenyl, alkynyl, alkylene chain, alkenylene chain and / or alkynylene chain may be cyclic or cycle containing when they include at least three carbon atoms.

[0992]

[0103] In some aspects, the compound of Formula I or of any of the formulas described within this application is suitable for making a lipid composition, which is suitable for the preparation of lipid nanoparticles.

[0993]

[0104] In some aspects, the compound of Formula I or Formula II is selected from the group of following compounds and their pharmaceutically acceptable salts or solvates thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0994] ADA905026L O ', ' L I Ml HN *1" '*">

[0995] ADA905022L ADA905018L

[0996]

[0997] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[0998] ADA901764L \ / \Z\ / X / \ZXzN

[0999]

[1000] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1001] °,r, ■ L J NH UN ' 1- <“X ADA901742L

[1002]

[1003] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1004]

[1005] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1006] O O -f". \ l l / ’ NH HN1' " Vi0■'NHADA901867L

[1007]

[1008] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1009]

[1010] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1011]

[1012] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1013]

[1014] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1015]

[1016] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1017]

[1018] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1019]

[1020] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1021]

[1022] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1023]

[1024] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1025]

[1026] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1027]

[1028] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1029] ADA005034L

[1030]

[1031] ADA005036L DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1032]

[1033] ADA005008L DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1034] ADA005013L

[1035]

[1036] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1037] ADA005015L

[1038]

[1039] ADA005039L DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1040]

[1041] ADA003018L DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1042] ADA003021L

[1043]

[1044] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1045] ADA003017L

[1046]

[1047] ADA000012L DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1048] ADA003033L

[1049]

[1050] ADA005041L

[1051]

[0105] In some aspects, the compounds of Formula I may be insoluble in water. The solubility of compounds of Formula I in water may virtually be undetectable without extremely specialized equipment.

[1052]

[0106] Preferably, the compounds of Formula I may be soluble in alcohols e.g. in ethanol or isopropanol. In some aspects, the compounds of Formula I may comprise amino moieties. In some aspects, these amino moieties may be protonated and the compounds of Formula I may exhibit a DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1053] positive charge. The compounds of Formula I may therefore be referred to as ionizable compounds or cationic compounds.

[1054]

[0107] In some aspects, the compounds of Formula I may comprise two amino moieties.

[1055]

[0108] In some aspects, the compounds of Formula I may comprise two tertiary amine groups.

[1056]

[0109] When the compounds of Formula I include one or more chiral centers, the Formulas I and II include pure enantiomers and / or mixture of enantiomers, including the racemate.

[1057]

[0110] Definitions

[1058]

[0111] As used herein, the term “alkyl” means a saturated hydrocarbon chain which may be linear, branched or cyclic or cycle containing, wherein said hydrocarbon chain includes one or more carbon atoms (e.g., one, two, three, four, or more carbon atoms), and which is derived from an alkane by removal of one hydrogen atom.

[1059]

[0112] As used herein, the term “alkenyl” means a hydrocarbon chain comprising at least one double bond between carbon atoms, and which is derived from an alkene by removal of one hydrogen atom. The hydrocarbon chain may be linear, branched or cyclic or cycle-containing. The hydrocarbon chain includes two or more carbon atoms (e.g. two, three, four or more). An alkenyl may include one, two or more carbon-carbon double bonds.

[1060]

[0113] As used herein, the term “alkynyl” means a hydrocarbon chain comprising at least one triple bond between carbon atoms, and which is derived from an alkyne by removal of one hydrogen atom. The hydrocarbon chain may be linear, branched or cyclic or cycle-containing. The hydrocarbon chain includes two or more carbon atoms (e.g. two, three, four or more). An alkynyl group may include one, two or more carbon-carbon triple bonds.

[1061]

[0114] As used herein, the term “alkylene chain” means a saturated hydrocarbon chain, which may be linear, branched or cyclic or saturated cycle-containing. The alkylene chain has two valencies, i.e. it is derived from an alkane by removal of two hydrogen atoms from different carbon atoms, binds as a linker or bridge via two bonds.

[1062]

[0115] As used herein, the term “alkenylene chain” means a hydrocarbon chain comprising a double bond. The alkenylene chain may be linear, branched, cyclic or cycle-containing comprising the DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1063] double bond. The alkenylene chain has two valencies, i.e. it binds as a linker or bridge via two bonds.

[1064]

[0116] As used herein, the term “alkynylene chain” means a hydrocarbon chain comprising a triple bond. The alkynylene chain may be linear, branched or cyclic or cycle-containing comprising the triple bond. The alkynylene chain has two valencies, i.e. it binds as a linker or bridge via two bonds. The alkynylene chain comprises one or more CH2groups on each of its ends.

[1065]

[0117] As used herein, the term “arylene comprising chain” means an aryl cycle with two substituents, wherein each substituent binds as a linker via a bond.

[1066]

[0118] As used herein, the term “compound of Formula I” or “compound of Formula II” is meant to include all isomers and isotopes of the depicted structures of the disclosure.

[1067]

[0119] As used herein, the term “component” means any compound of Formula I, structural lipids, sterols and / or stabilizing agent.

[1068]

[0120] As used herein, the term “lipid composition” means a mixture comprising a compound of Formula I and at least one component of a group selected from the group consisting of: structural lipids, sterols and stabilizing agents.

[1069]

[0121] As used herein, the term “contacting” means establishing a physical connection between two or more entities. For example, contacting a cell with a lipid composition and / or the LNPs means that the cell and the lipid composition and / or the LNPs are made to share a physical connection. Methods of contacting cells with external entities both in vivo and ex vivo are well known in the biological arts. For example, contacting the lipid composition or the LNPs and a mammalian cell disposed within a mammal may be performed by varied routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve varied amounts of lipid composition and / or lipid nanoparticles (e.g., payload-free LNPs or loaded LNPs). Moreover, more than one cell may be contacted by the composition or the LNPs.

[1070]

[0122] As used herein, the term “encapsulation efficiency" describes the amount of the payload that is encapsulated or otherwise associated with LNPs after preparation, relative to the initial amount provided. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1071]

[0123] As used herein, the terms “encapsulation”, “encapsulated”, “loaded”, and “associated” refers to complete, substantial, or partial enclosure, confinement, surrounding, or encasement. As used herein, “encapsulation” or “association” may refer to the process of confining one or more individual nucleic acid molecules within a nanoparticle and / or establishing a physicochemical relationship between an individual nucleic acid molecule and a nanoparticle.

[1072]

[0124] As used herein, the term “ex vivo” refers to events that occur outside of an organism (e.g.

[1073] human, animal, plant, or microbe or cell or tissue thereof). Ex vivo events may take place in an environment minimally altered from a natural (e.g., in vivo) environment.

[1074]

[0125] As used herein, the term “helper lipid” refers to structural lipids, sterols and / or stabilizing agents.

[1075]

[0126] As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).

[1076]

[0127] As used herein, the term “in vivo” refers to events that occur within an organism (e.g. human, animal, plant, or microbe or cell or tissue thereof).

[1077]

[0128] As used herein, an “ionizable compound” refers to a chemical substance that can gain or lose protons under specific pH conditions, resulting in the formation of positively or negatively charged ions.

[1078]

[0129] As used herein, the term “isomer” means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound.

[1079]

[0130] As used herein, the term “lipid nanoparticle” refers to a particle formed from lipid composition by self-assembly by any method, e.g. by use of microfluidic device. The nanoparticles may comprise loaded lipid nanoparticles or empty nanoparticles

[1080]

[0131] As used herein, the term “loaded lipid nanoparticle” refers to a lipid nanoparticle comprising a payload.

[1081]

[0132] As used herein, the term “empty lipid nanoparticle” refers to a lipid nanoparticle including no payload. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1082]

[0133] As used herein, the term “N: P ratio” is the molar ratio of ionizable (in the physiological pH range) nitrogen atoms in a lipid to phosphate groups in an RNA, e.g., in a nanoparticle composition including a compound of Formula I, at least one component and an RNA.

[1083]

[0134] As used herein, the term “nucleic acid” refers to and includes ribonucleic acid (RNA), deoxyribonucleic acid (DNA), antisense oligonucleotides or peptide nucleic acid (PNA) that may be naturally or non-naturally occurring. DNA may be single-stranded DNA, double-stranded DNA, cDNA and plasmid DNA encoding a gene or genes. RNA may be messenger RNA (mRNA), transfer RNA (tRNA), small interfering RNA (siRNA), double-stranded RNA, micro- RNA (miRNA), piwi-RNA (piRNA), antisense RNA (asRNA), guide RNA (gRNA) for the CRISPR system and their combinations (typically e.g. gRNA and mRNA encoding Cas9 nuclease, Cas13a / C2c2 and Cas13b, or analogous nucleases, suitable for use in CRISPR, CRISPRi and other variations and subsequent modifications of the host cell or tissue genome or modification of the host cell or tissue transcriptome). The nucleic acid may include one or more naturally occurring, modified or non-naturally occurring parts including but not limited to nucleobases, nucleosides and / or nucleotides. Such modifications may include phosphorylation at the 5' or 3' end of the strand, or at both the 5' or 3' end of the strand, 5-methylcytidine-5'-triphosphate, N1-methylpseudouridine-5'-triphosphate, P1-(5'-(3'-O-methyl)-7-methyl-guanosyl)-P3-(5'-(guanosyl))triphosphate, P1-(guanosyl) P3-(5'-(guanosyl))tri- phosphate, P1-(5'-7-methyl-guanosyl) P3-(5'-(guanosyl))triphosphate, P1- (5'-2,2,7-trimethyl-guanosyl) P3-(5'-(guanosyl))triphosphate, N6-methyladenosine-5'-triphosphate, 2-thiouridine-5'-triphosphate, pseudouridine- 5 ' -triphosphate, 5 -methoxyur idine- 5 ' -triphosphate, N 1 -methyladenosine-5'-triphosphate, / V4-acetylcytidine-5'-triphosphate, 2'-O-methyl, 2'-O-methoxyethyl, 2'-fluoro, a methylene bridge between the 2'-oxygen and the 4'-carbon of the pentose ring (a so-called locked nucleic acid), boranophosphonates, or phosphorothioates or other modifications known in the art.

[1084]

[0135] As used herein the term “payload” refers to and includes any compound that, when administered to a subject, has a therapeutic, diagnostic, or prophylactic effect and elicits a desired biological and pharmacological effect, or has both a biological and pharmaceutical effect. The payload refers to and includes a therapeutic agent, diagnostic agent, prophylactic agent and DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1085] combinations thereof. The payload may comprise naturally or non-naturally occurring compounds. Such compounds consist of cyclic dinucleotides and / or nucleic acids.

[1086]

[0136] As used herein, the term “pharmaceutically acceptable salts” refers to derivatives of the compounds of Formula I wherein the compound is derived by converting its acid or base moiety to its salt form, e.g., by reacting a free base group with a suitable organic or inorganic acid. Representative acid salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesuphonate, benzoate, besylate, bicarbonate, bitartrate, bisulphate, borate, bromide, butyrate, camsylate, carbonate, chloride, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, decanoate, digluconate, dodecylsulfate, edeate, esylate, ethanesulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy- ethanesulfonate,, iodide, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, mesylate, methansuplhate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, octanoate, oleate, oxalate, palmitate, palmoate, panthotenate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, succinate, sulphate, tartrate, thiocyanate, tosylate, toluenesulfonate, undecanoate, valerate salts, and the like. Other representative salts include sodium, lithium, potassium, calcium, magnesium. Yet other representative salts include salts such as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non- toxic salts of the disclosed compound of Formula I formed, for example, from non-toxic inorganic or organic acids.

[1087]

[0137] As used herein, the terms “polydispersity index” and “PDI” refer to a ratio that describes the homogeneity of the particle size distribution of a system. A small value, e.g., less than 0.3, indicates a narrow particle size distribution.

[1088]

[0138] As used herein, the term “protein” refers to a chain of amino acid residues that may be naturally or non-naturally occurring. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1089]

[0139] As used herein, the terms “size” or “mean size” in the context of lipid nanoparticles (e.g., payload-LNPs or loaded LNPs) refer to the mean diameter of a nanoparticle composition.

[1090]

[0140] As used herein, the term “stabilizing agent” refers to lipid conjugate with hydrophilic polymer, wherein said lipid conjugate comprises a lipid portion and a polymer portion such as poly(ethyleneglycol), poly(2-ethyl-2-oxazoline), poly(2-methyl-2-oxazoline), poly(glycerol), poly(N- (2-hydroxypropyl) methacrylamide), poly(sarcosine) or glycol chitosan. Lipid conjugate with hydrophilic polymer may, for example, be selected from the group comprising: 1,2- dimyristoyl-rac-glycero-3-methoxypoly(ethyleneglycol)-2000,

[1091] 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000

[1092] (DMG-PEG2000),

[1093] 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000,

[1094] 1.2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000, and the like.

[1095]

[0141] As used herein, the term “sterol” refers to a compound comprising sterol core and is selected from the group comprising cholesterol, 7-hydroxycholesterol, β-sitosterol, stigmastanol, campesterol, fucosterol, avenasterol, fecosterol, brassicasterol, ergosterol, coprostanol and 9, 11 -dehydroergosterol.

[1096]

[0142] As used herein the term, “structural lipid” refers to neutral, cationic and anionic lipids.

[1097] Structural lipid is selected from the group comprising:

[1098] 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),

[1099] 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE),

[1100] 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE),

[1101] 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),

[1102] 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),

[1103] 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),

[1104] 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), and

[1105] 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine-N-(Cyanine 5),

[1106] 1.2-dioleoyl-3-dimethylammonium-propane (DODAP),

[1107] 1.2-dioleoyl-3-trimethylammonium-propane (DOTAP),

[1108] 1.2-dilinoleoyl-sn-gly cero-3 -phosphocholine (DLPC),

[1109] 1.2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1110] 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),

[1111] 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),

[1112] 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC),

[1113] 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),

[1114] 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),

[1115] 1,2-dilinolenoyl-sn-glycero-3-phosphocholine,

[1116] 1,2-diarachidonoyl-sn-glycero-3-phosphocholine,

[1117] 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,

[1118] 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),

[1119] 1,2-distearoyl-sn-glycero-3-phosphoethanolamine,

[1120] 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,

[1121] 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,

[1122] 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,

[1123] 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,

[1124] 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), diphytanoylphosphatidylcholine (DPhPC), dioleoyl-3 -trimethylammonium propane (DO AB), dierucoylphosphatidylcholine (DEPC), dilinoleoylphosphatidylcholine (DEPC) and sphingomyelin.

[1125]

[0143] As used herein, the term “transfection” refers to the introduction of a species (e.g., an RNA) into a cell. Transfection may occur, for example, in vitro, ex vivo, or in vivo.

[1126] DETAILED DESCRIPTION

[1127]

[0144] The present disclosure provides compounds (e.g. ionizable compounds) that play important part in lipid nanoparticles (LNPs) and which display exceptional characteristics in lipid nanoparticles delivery and payload release. Lipid nanoparticles may be created by assembly, including a self-assembly. Lipid nanoparticles may be engineered to be used as vehicle, which may encapsulate payload. Encapsulating therapeutic agents in LNPs ensures their stability and delivery into a specific site of action. In living systems lipid nanoparticles may be dispersed into the bloodstream and may circulate throughout and be internalized into cells. Once inside the cell, the lipid nanoparticles may be trafficked through the endosomal pathway. The acidic environment DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1128] within the endosome may trigger the release of the therapeutic agent from the LNPs. The ionizable compound may play a crucial role in this process, as it can destabilize the endosomal membrane and facilitate the escape of the therapeutic cargo into the cytoplasm.

[1129]

[0145] The present disclosure refers to compounds of Formula I, Formula II and Formula III.

[1130]

[0146] In some aspects, compounds of Formula I may comprise ionizable compounds. In some aspects, the compounds of Formula I may comprise lipidoids. Lipidoids may be synthetic molecules similar to lipids.

[1131]

[0147] The present disclosure also refers to a lipid composition.

[1132]

[0148] In some aspects, the lipid composition may comprise at least one compound of Formula I and at least one helper lipid, wherein said helper lipid may be selected from the group consisting of: structural lipids, sterols, stabilizing agents and / or any combinations thereof. Since compounds of Formula II and Formula III are a subset of the compounds of Formula I, any aspect described in relation to Formula I may also apply to Formula II and Formula III unless otherwise mentioned.

[1133]

[0149] In some aspects, the lipid composition may comprise at least one compound of Formula I, a structural lipid, a sterol and / or a stabilizing agent.

[1134]

[0150] In some aspects, the lipid composition may comprise at least one compound of Formula I, and at least one structural lipid.

[1135]

[0151] In some aspects, the lipid composition may comprise at least one compound of Formula I, and at least one sterol.

[1136]

[0152] In some aspects, the lipid composition may comprise at least one compound of Formula I and at least one stabilizing agent.

[1137]

[0153] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, a sterol and a stabilizing agent.

[1138]

[0154] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE and / or DSPC, a sterol, a stabilizing agent and combinations thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1139]

[0155] In some aspects, the lipid composition may comprise at least one compound of Formula I, at least one structural lipid, cholesterol and at least one stabilizing agent.

[1140]

[0156] In some aspects, the lipid composition may comprise at least one compound of Formula I, at least one structural lipid, β-sitosterol and / or at least one stabilizing agent.

[1141]

[0157] In some aspects, the lipid composition may comprise at least one compound of Formula I, at least one structural lipid, cholesterol, β-sitosterol and / or at least one stabilizing agent.

[1142]

[0158] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, β-sitosterol and / or at least one stabilizing agent.

[1143]

[0159] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, β-sitosterol and / or at least one stabilizing agent.

[1144]

[0160] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, DSPC, β-sitosterol and / or at least one stabilizing agent.

[1145]

[0161] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, β-sitosterol and DMG-PEG2000.

[1146]

[0162] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, β-sitosterol and DMG-PEG2000.

[1147]

[0163] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, DSPC, β-sitosterol and DMG-PEG2000.

[1148]

[0164] In some aspects, the lipid composition may comprise a compound of Formual I, at least one structural lipid, 7-hydroxycholesterol and / or at least one stabilizing agent.

[1149]

[0165] In some aspects, the lipid composition may comprise a compound of Formula I, at least one structural lipid, 7-hydroxycholesterol, cholesterol and / or at least one stabilizing agent.

[1150]

[0166] In some aspects, the lipid composition may comprise a compound of Formula I, DOPE and / or DSPC, 7-hydroxycholesterol and / or cholesterol and / or at least one stabilizing agent and / or any combination thereof. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1151]

[0167] In some aspects, the lipid composition may comprise a compound of Formula I, at least one structural lipid, 7-hydroxycholesterol and / or cholesterol and DMG-PEG2000 and / or any combination thereof.

[1152]

[0168] In some aspects, the lipid composition may comprise a compound of Formula I, DOPE and / or DSPC, 7-hydroxycholesterol and / or cholesterol and DMG-PEG2000 and / or any combination thereof.

[1153]

[0169] In some aspects the lipid composition may comprise at least one compound of Formula I, DOPE, cholesterol, and stabilizing agent.

[1154]

[0170] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, at least one sterol and DMG-PEG2000.

[1155]

[0171] In some aspects, the lipid composition may comprise at least one compound of Formula I, DOPE, cholesterol, β-sitosterol and at least one stabilizing agent.

[1156]

[0172] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, cholesterol, β-sitosterol and at least one stabilizing agent.

[1157]

[0173] In some aspects, the lipid composition may comprise at least one compound of Formula I, cholesterol, β-sitosterol and DMG-PEG2000.

[1158]

[0174] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, at least one sterol and / or at least one stabilizing agent.

[1159]

[0175] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, cholesterol and at least one stabilizing agent.

[1160]

[0176] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, cholesterol, β-sitosterol and / or at least one stabilizing agent.

[1161]

[0177] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, cholesterol and DMG-PEG2000.

[1162]

[0178] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, at least one sterol and DMG-PEG2000. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1163]

[0179] In some aspects, the lipid composition may comprise a compound of Formula I, DOPE, cholesterol and DMG-PEG2000.

[1164]

[0180] In some aspects, the lipid composition may comprise a compound of Formula I, DOPE and / or DSPC, cholesterol, DMG-PEG2000 and combination thereof.

[1165]

[0181] In some aspects, the lipid composition may comprise a compound of Formula I in a range of 2.5 to 80 mol % or 10 to 70 mol % or 20 to 60 mol % or 25 to 55 mol % or 30 to 50 mol % or 30 to 40 mol % of the lipid composition.

[1166]

[0182] In some aspects, the lipid composition may comprise a structural lipid in a range of 2.5 to 80 mol % or 5 to 60 mol % or 5 to 50 mol % or 10 to 40 mol % or 10 to 30 mol % or 20 to 30 mol % of the lipid composition.

[1167]

[0183] In some aspects, the lipid composition may comprise DOPE in a range of 2.5 to 80 mol % or 5 to 60 mol % or 5 to 50 mol % or 10 to 40 mol % or 10 to 30 mol % or 20 to 30 mol % or 10 to 15 mol % of the lipid composition.

[1168]

[0184] In some aspects, the lipid composition may comprise DSPC in a range of 2.5 to 80 mol % or 5 to 60 mol % or 5 to 50 mol % or 10 to 40 mol % or 10 to 30 mol % or 20 to 30 mol % or 10 to 15 mol % of the lipid composition.

[1169]

[0185] In some aspects, the lipid composition may comprise POPE in a range of 2.5 to 80 mol % or 5 to 60 mol % or 5 to 50 mol % or 10 to 40 mol % or 10 to 30 mol % or 20 to 30 mol % or 10 to 15 mol % of the lipid composition.

[1170]

[0186] In some aspects, the lipid composition may comprise SOPE in a range of 2.5 to 80 mol % or 5 to 60 mol % or 5 to 50 mol % or 10 to 40 mol % or 10 to 30 mol % or 20 to 30 mol % or 10 to 15 mol % of the lipid composition.

[1171]

[0187] In some aspects, the lipid composition may comprise a sterol in a range of 2.5 to 80 mol % or 10 to 70 mol % or 20 to 60 mol % or 30 to 50 mol % or 35 to 45 mol % of the lipid composition.

[1172]

[0188] In some aspects, the lipid composition may comprise cholesterol in a range of 2.5 to 80 mol % or 10 to 70 mol % or 20 to 60 mol % or 30 to 50 mol % or 35 to 45 mol % of the lipid composition. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1173]

[0189] In some aspects, the lipid composition may comprise β-sitosterol in a range of 2.5 to 80 mol % or 10 to 70 mol % or 20 to 60 mol % or 30 to 50 mol % or 35 to 45 mol % of the lipid composition.

[1174]

[0190] In some aspects, the lipid composition may comprise 7-hydroxycholesterol in a range of 2.5 to 80 mol % or 10 to 70 mol % or 20 to 60 mol % or 30 to 50 mol % or 35 to 45 mol % of the lipid composition.

[1175]

[0191] In some aspects, the lipid composition may comprise a stabilizing agent in a range of 0.1 to 90 mol % or 0.5 to 60 mol % or 0.5 to 20 mol % or 0.5 to 15 mol % or 0.8 to 15 mol % or 0.8 to 10 mol % or 0.8 to 5 mol % or 0.8 to 1.8 mol % or 1.1 to 5 mol % or of 1.1 to 2 mol % or 1.2 to 1.8 mol % of the lipid composition.

[1176]

[0192] In some aspects, the lipid composition may comprise DMG-PEG2000 in a range of 0.1 to 90 mol % or 0.5 to 60 mol % or 0.5 to 20 mol % or 0.5 to 15 mol % or 0.8 to 15 mol % or 0.8 to 10 mol % or 0.8 to 5 mol % or 0.8 to 1.8 mol % or 1.1 to 5 mol % or of 1.1 to 2 mol % or 1.2 to 1.8 mol % of the lipid composition.

[1177]

[0193] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 2.5 to 80 mol %, at least one structural lipid in a range of 2.5 to 80 mol %, at least one sterol in a range of 2.5 to 80 mol % and at least one stabilizing agent in a range of 0.1 to 90 mol %.

[1178]

[0194] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, at least one structural lipid in a range of 20 to 30 mol %, at least one sterol in a range of 35 to 45 mol % and at least one stabilizing agent in a range of 1.2 to 1.8 mol %.

[1179]

[0195] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DOPE in a range of 20 to 30 mol %, cholesterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1180]

[0196] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, combination of DOPE and DSPC, wherein total molar percentage of the DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1181] combination of DOPE and DSPC may be in a range of 20 to 30 mol %, cholesterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1182]

[0197] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DOPE in a range of 5 to 30 mol %, DSPC in a range of 5 to 30 mol %, cholesterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1183]

[0198] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DOPE in a range of 10 to 15 mol %, DSPC in a range of 10 to 15 mol %, cholesterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1184]

[0199] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DOPE in a range of 20 to 30 mol %, β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1185]

[0200] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DSPC in a range of 20 to 30 mol %, β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1186]

[0201] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DOPE in a range of 5 to 30 mol %, DSPC in a range of 5 to 30 mol %, β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1187]

[0202] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, DSPC in a range of 20 to 30 mol %, cholesterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1188]

[0203] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, SOPE in a range of 20 to 30 mol %, β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1189]

[0204] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, POPE in a range of 20 to 30 mol %, β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1190]

[0205] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, combination of DOPE and DSPC, wherein total molar percentage of combination of DOPE and DSPC may be in a range of 20 to 30 mol % β-sitosterol in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1191]

[0206] In some aspects, the lipid composition may comprise at least one compound of Formula I in a range of 30 to 40 mol %, combination of DOPE and DSPC, wherein total molar percentage of DOPE and DSPC may be in a range of 20 to 30 mol %, combination of cholesterol and 7- hydroxycholesterol, wherein total molar percentage of cholesterol and 7-hydroxycholesterol may be in a range of 35 to 45 mol % and DMG-PEG2000 in a range of 1.2 to 1.8 mol %.

[1192]

[0207] In some aspects, the lipid composition may further comprise at least one payload.

[1193]

[0208] In some aspects, the lipid composition may comprise at least one nucleic acid.

[1194]

[0209] In some aspects, the lipid composition may comprise at least one ionizable compound of Formula I, at least one payload and / or at least one helper lipid and combinations thereof, wherein said helper lipid may be selected from the group comprising structural lipids, sterols, stabilizing agents and combinations thereof.

[1195]

[0210] In some aspects, the lipid composition may comprise at least one ionizable compound of Formula I, DOPE, a sterol, a stabilizing agent and at least one nucleic acid.

[1196]

[0211] In some aspects, the lipid composition may comprise at least one compound of Formula I, DSPC, at least one sterol, at least one stabilizing agent and at least one nucleic acid.

[1197]

[0212] In some aspects, the lipid composition may comprise at least one compound of Formula I, POPE, at least one sterol, at least one stabilizing agent and at least one nucleic acid.

[1198]

[0213] In some aspects, the lipid composition may comprise at least one compound of Formula I, SOPE, at least one sterol, at least one stabilizing agent and at least one nucleic acid.

[1199]

[0214] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, DOPE, cholesterol, stabilizing agent and at least one nucleic acid. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1200]

[0215] In some aspects, the lipid composition may comprise a compound of Formula I, DOPE, β-sitosterol, stabilizing agent and at least one nucleic acid.

[1201]

[0216] In some aspects, the lipid composition may comprise a compound of Formula I, DSPC, β-sitosterol, stabilizing agent and at least one nucleic acid.

[1202]

[0217] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, DSPC, cholesterol, stabilizing agent and at least one nucleic acid.

[1203]

[0218] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, POPE, β-sitosterol, stabilizing agent and at least one nucleic acid.

[1204]

[0219] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, SOPE, β-sitosterol, stabilizing agent and at least one nucleic acid.

[1205]

[0220] In some aspects, the lipid composition may comprise ionizable compound of Formula I, DOPE, cholesterol, DMG-PEG2000, at least one nucleic acid.

[1206]

[0221] In some aspects, the lipid composition may comprise ionizable compound of Formula I, DOPE, β-sitosterol, DMG-PEG2000, at least one nucleic acid.

[1207]

[0222] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, DSPC, β-sitosterol, DMG-PEG2000 and at least one nucleic acid.

[1208]

[0223] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, DSPC, cholesterol, DMG-PEG2000 and at least one nucleic acid.

[1209]

[0224] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, POPE, β-sitosterol, DMG-PEG2000 and at least one nucleic acid.

[1210]

[0225] In some aspects, the lipid composition may comprise an ionizable compound of Formula I, SOPE, β-sitosterol, DMG-PEG2000 and at least one nucleic acid.

[1211]

[0226] In some aspects, the lipid composition may comprise at least one compound of Formula I, combination of DOPE and DSPC, β-sitosterol and DMG-PEG2000 and at least one nucleic acid. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1212]

[0227] In some aspects, the lipid composition may comprise at least one compound of Formula I, combination of DOPE and DSPC, combination of cholesterol and 7-hydroxycholesterol and DMG-PEG2000 and at least one nucleic acid.

[1213]

[0228] In some aspects, the lipid composition may be prepared in the form of a solution by mixing at least two components including at least one compound of Formula I in a solvent. In some aspects, the lipid composition may also be prepared in the solid form by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing and lyophilization.

[1214]

[0229] In some aspects, lipid composition may be prepared by combining at least one compound of Formula I and at least one helper lipid in organic solvent (e.g. an alcohol such as ethanol).

[1215]

[0230] In some aspects, lipid composition may be prepared by combining a compound of Formula I, structural lipid, a sterol and a stabilizing agent in organic solvent (e.g. alcohol such as ethanol).

[1216]

[0231] In some aspects, lipid composition may be prepared by combining compound of Formula I, DOPE, cholesterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1217]

[0232] In some aspects, lipid composition may be prepared by combining compound of Formula I, DOPE, β-sitosterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1218]

[0233] In some aspects, lipid composition may be prepared by combining compound of Formula I, DSPC, cholesterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1219]

[0234] In some aspects, lipid composition may be prepared by combining compound of Formula I, DSPC, β-sitosterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1220]

[0235] In some aspects, lipid composition may be prepared by combining compound of Formula I, combination of DOPE and DSPC, cholesterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1221]

[0236] In some aspects, lipid composition may be prepared by combining compound of Formula I, combination of DOPE and DSPC, β-sitosterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol). DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1222]

[0237] In some aspects, lipid composition may be prepared by combining compound of Formula I, combination of DOPE and DSPC, combination of cholesterol and 7-hydroxycholesterol and DMG-PEG2000 in organic solvent (e.g. alcohol such as ethanol).

[1223]

[0238] The present disclosure also refers to lipid nanoparticles.

[1224]

[0239] In some aspects, the lipid nanoparticles may comprise loaded lipid nanoparticles.

[1225]

[0240] In some aspects, the lipid nanoparticles may comprise empty lipid nanoparticles. In some aspects, the empty lipid nanoparticles may be prepared by mixing the lipid composition. In some aspects, empty lipid nanoparticles may be prepared by mixing lipid composition e.g. in a microfluidic device. In some aspects, empty lipid nanoparticles may be prepared by mixing lipid composition dissolved in organic solvent e.g. using a microfluidic device. In some aspects, empty lipid nanoparticles may be prepared by mixing lipid composition dissolved in alcohol.

[1226]

[0241] In some aspects, loaded lipid nanoparticles may be formed from lipid composition. Disclosed ratios of the lipid compositions may preferably be identical for the lipid nanoparticles. In some aspects, lipid nanoparticles may comprise a solid core. The solid core may be defined as a core which may lack any substantial aqueous content in its center. The solid lipid core may provide enhanced stability by maintaining the structural integrity of the encapsulated pay load, which may be in some aspects present.

[1227]

[0242] In some aspects, the lipid nanoparticles may be prepared by mixing the lipid composition and one or more payloads. In some aspects, lipid nanoparticles may be prepared by mixing lipid composition and one or more payloads e.g. in a microfluidic device. In some aspects, lipid nanoparticles may be prepared by mixing lipid composition dissolved in organic solvent and one or more payloads dissolved in an aqueous solution e.g. using a microfluidic device. In some aspects, lipid nanoparticles may be prepared by mixing lipid composition dissolved in alcohol and one or more pay loads dissolved in a buffer e.g. using a microfluidic device.

[1228]

[0243] In some aspects, the lipid nanoparticles may be prepared by mixing the lipid composition and nucleic acid in a buffer. In some aspects, lipid nanoparticles may be prepared by mixing lipid composition and nucleic acid in a buffer in a microfluidic device. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1229]

[0244] In some aspects, lipid nanoparticles may be prepared by mixing lipid composition and nucleic acid in a citrate buffer in “Y” shaped microfluidic device with two inputs and one output.

[1230]

[0245] In some aspects, lipid nanoparticles may be prepared by mixing lipid composition and nucleic acid in a acetate buffer in Ignite NxGen microfluidic chip.

[1231]

[0246] Empty LNPs may be formed from lipid composition using mixing. The mixing may be performed by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing.

[1232]

[0247] In some aspects, empty LNP may comprise at least one compound of Formula I and at least one helper lipid.

[1233]

[0248] In some aspects, empty LNP may comprise at least one compound of Formula I, at least one structural lipid, at least one sterol and / or at least one stabilizing agent.

[1234]

[0249] In some aspects, empty LNP may comprise at least one compound of Formula I, DOPE, cholesterol and DMG-PEG2000.

[1235]

[0250] In some aspects, empty LNP may comprise at least one compound of Formula I, DOPE, 0- sitosterol and DMG-PEG2000.

[1236]

[0251] In some aspects, empty LNP may comprise at least one compound of Formula I, DSPC, 0- sitosterol and DMG-PEG2000.

[1237]

[0252] In some aspects, empty LNP may comprise at least one compound of Formula I, DOPE, DSPC, 0-sitosterol and DMG-PEG2000.

[1238]

[0253] In some aspects, lipid nanoparticles may be prepared, by mixing a solution of compound of Formula I with a solution of the payload. Mixing may be performed by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing.

[1239]

[0254] In some aspects, lipid nanoparticles may be prepared, by mixing a solution of compound of Formula I and at least one helper lipid with a solution of the payload. Mixing may be performed by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1240]

[0255] In some aspects, lipid nanoparticles may be prepared by mixing a solution of compound of Formula I, structural lipid, a sterol and a stabilizing agent with a solution of the payload. Mixing may be performed by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing.

[1241]

[0256] In some aspects, lipid nanoparticles may be prepared, for example, by mixing a solution of compound of Formula I, DOPE, cholesterol and DMG-PEG2000 with a solution of the payload Mixing may be performed by means of techniques used in conventional nanoparticle technology, for example, by microfluidic mixing.

[1242]

[0257] Lipid nanoparticles may be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) may be used to examine the morphology and size distribution of a lipid nanoparticle. Dynamic light scattering or potentiometry (e.g., potentiometric titrations) may be used to measure zeta potentials. Dynamic light scattering may also be utilized to determine particle sizes. Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) may also be used to measure multiple characteristics of a lipid nanoparticle, such as particle size, polydispersity index, and zeta potential.

[1243]

[0258] The mean size of the lipid nanoparticle, may be between tens of nm and hundreds of nm, as measured by e.g. dynamic light scattering (DLS). In some aspects the mean size of prepared LNPs may be in the range of 10 to 500 nm or in the range of 15 to 360 nm or in the range of 20 to 350 nm or in the range of 20 to 330 nm or in the range of 25 to 300 nm or in the range of 30 to 250 nm or in the range of 40 to 200 nm or in the range of 50 to 150 nm.

[1244]

[0259] The lipid nanoparticle’s size distribution may be relatively homogenous. A polydispersity index may be used to indicate the homogeneity of lipid nanoparticles, e.g. the particle size distribution of the lipid nanoparticle. A small (e.g. less than 0.3) poly dispersity index may generally indicate a narrow particle size distribution. Prepared lipid nanoparticles may have a polydispersity index in the range of 0.01 to 0.3 or in the range of 0.01 to 0.25 or in the range of 0.01 to 0.2 or in the range of 0.05 to 0.2 or in the range of 0.1 to 0.2.

[1245]

[0260] In some aspects, a loaded lipid nanoparticle may include one or more RNAs. One or more RNAs, compounds of Formula I, and amounts thereof may be selected to provide a specific N: P DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1246] ratio. The N: P ratio of the loaded LNP may refer to the molar ratio of nitrogen atoms in one or more compounds of Formula I to the number of phosphate groups in an RNA. The one or more RNA, compounds of Formula I, and amounts thereof may be selected to provide an N: P ratio in the range of 1: 1 to 50: 1, or in the range of 2:1 to 30:1 or in the range of 3:1 to 20:1 or in the range of 3:1 to 10:1 or in the range of 3:1 to 7:1 or in the range of 3:1 to 6:1.

[1247]

[0261] The encapsulation efficiency may be desirably high (e.g. close to 100%). The encapsulation efficiency may be measured, for example, by comparing the amount of the payload in a solution containing the LNP before and after breaking up the LNP with one or more organic solvents or detergents. Fluorescence may be used to measure the amount of free payload (e.g. RNA or DNA) in a solution. For the LNPs described herein, the encapsulation efficiency of the payload may be at least 50% or at least 60% or at least 70% or at least 80% or at least 90% or at least 95%.

[1248]

[0262] The lipid composition and / or LNPs of the present disclosure may be used in transfecting cells and / or tissues with nucleic acid and / or any other therapeutic agent in vitro.

[1249]

[0263] The lipid composition and / or LNPs of the present disclosure may also be used in transfecting cells and / or tissues and / or organs and / or any other part of living system or living organism with nucleic acid and / or any other therapeutic agent in vivo (excluding the transfection of human embryos for industrial or commercial use, and excluding the modification of human germ line). The lipid composition and / or LNPs may be administered to a living system by contacting the cell with the lipid composition and / or LNP, whereby the payload may be delivered to the cell.

[1250]

[0264] The lipid composition and / or LNPs of the present disclosure may also be used in transfecting cells and / or tissues and / or organs and / or any other part of living system with nucleic acid and / or any other therapeutic agent ex vivo (excluding transfection of human embryos for industrial or commercial use and excluding the modification of human germ line).

[1251]

[0265] The lipid composition and / or LNPs containing compounds of Formula I may be used for therapeutic and / or prophylactic purposes in veterinary and human medicine. Said particles containing nucleic acid and / or any other therapeutic agent may be administered to an animal and / or human to silence and / or activate gene(s), in particular chromosomal gene(s), to silence and / or activate immunogens, to inhibit and / or activate signaling pathways, to edit the genome and / or the transcriptome and / or enable the expression of protein(s) encoded by the nucleic acid. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1252]

[0266] The lipid composition and / or LNPs containing compounds of Formula I may also be used as medicaments for gene therapy.

[1253]

[0267] Furthermore the lipid composition and / or LNPs containing compounds of Formula I may also be used for the purposes of the cosmetics industry in order to deliver the payload to a site of its action. The lipid composition and / or LNPs with payload may be prepared in the form of cream, gel, ointment, paste, balm, liquid or any other suitable form.

[1254]

[0268] The lipid composition and / or LNPs may be formulated for therapeutic, cosmetic or biotechnological use in the form of preparations with pharmaceutically acceptable excipients. The formulations may be in liquid or solid form, or in other forms, such as an aerosol. Liquid forms may include solutions, suspensions, dispersions, adapted e.g. for injection or oral administration. Solid forms may include, for example, capsules, tablets, coated tablets, powders, suppositories, and other forms. The liquid formulations may be nebulized. Nebulized suspensions may be breathed in directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, and / or intermittent positive pressure breathing machine. The solid dosage forms may also be administered via inhalation using dry-powder inhalers. Suspension and / or dry powder formulations may be administered orally or nasally from devices which may deliver the pharmaceutical composition. In order to deliver the payload (e.g. including active substance) on the skin or mucous membranes, the lipid composition and / or LNPs may be also prepared in the form of a cream, gel, ointment, paste, balm, liquid. These topical forms may be applied directly on the site of action or in the vicinity of the site of action. The site of action may comprise a skin, an internal organ, a blood vessel, a muscle, an adipose tissue, a dermis, a bone, a joint. Pharmaceutically acceptable excipients may include solvents, solubility control agents, pH adjusting agents, carriers, fillers, binders, glidants, disintegrants, preservatives, sorbents, viscosity control agents, agents that affect sensory properties such as taste, odor or the color of the formulation.

[1255]

[0269] In some aspects, the compounds of Formula I, lipid compositions and / or LNPs (e.g. loaded LNPs) may be refrigerated or frozen for storage and / or shipment using a temperature in the range of -150 to 4 °C or in the range of -100 to 0 °C or in the range of -90 to -10 °C or in the range of - 80 to -20 °C. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1256]

[0270] In some aspects, the compounds of Formula I, lipid compositions and / or LNPs may be formulated with a pharmaceutically acceptable carrier selected from the group comprising: Tris, an acetate (e.g., sodium acetate), a citrate (e.g., sodium citrate), saline, PBS, and sucrose or a combination thereof.

[1257]

[0271] In some aspects, the LNPs may also be formulated into the form of suspension by mixing said LNPs with a suitable pharmaceutically acceptable carrier, which may be selected from the group comprising: Tris, an acetate (e.g., sodium acetate), a citrate (e.g., sodium citrate), saline, PBS, and sucrose or any combination thereof. Said solution of at least one LNP and at least one pharmaceutically acceptable carrier may have a pH value in the range of 3 to 12 or in the range of 3.5 to 10 or in the range of 4 to 9 or in the range of 5 to 8.

[1258]

[0272] All aspects above may be combined. The foregoing description of preferred aspects has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Modification and variations are possible in light of the above teachings or may be acquired from practice of the invention and its practical application to enable one skilled in the art to utilize the invention. Various modifications as are suited to a particular use are contemplated.

[1259]

[0273] List of abbreviations:

[1260] °C degree Celsius

[1261] p micro

[1262] Ac acetyl

[1263] AdaOH 1 -adamantanol (CAS: 768-95-6)

[1264] ALT alanine aminotransferase

[1265] AMC mixture of 5 g phosphomolybdic acid hydrate, 2 g Ce(SO4)2, 12 mL concentrated H2SO4, 188 mL H2O

[1266] API active pharmaceutical ingredient DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1267] AST aspartate aminotransferase

[1268] Bl 0.1M benzylalcohol in 1,1,2, 2-tetrachloroethane (CAS: 100-51-6, CAS: 79-34-5)

[1269] B2 0.2M benzyl alcohol and 2.0M diisopropyl-ethylamine in

[1270] 1,1, 2, 2-tetrachloroethane (CAS: 100-51-6, CAS: 7087-68-5, CAS: 79-34-5)

[1271] Bn benzyl

[1272] Boc tert-butyloxycarbonyl

[1273] BOC2O di- / / 7-butyl di carbonate (CAS: 24424-99-5)

[1274] calcd. calculated

[1275] cat. catalyst

[1276] CDC13 deuterated chloroform (CAS: 865-49-6)

[1277] cDNA complementary deoxyribonucleic acid

[1278] CE5 95:5 (v / v) cyclohexane-ethylacetate mixture

[1279] CE50 50:50 (v / v) cyclohexane-ethylacetate mixture

[1280] Co. company

[1281] cone. concentrated

[1282] d day

[1283] DI 75:22:3 (v / v / v) dichloromethane-methanol-25% aqueous ammonia

[1284] Dlb 83:15:2 (v / v / v) dichloromethane-methanol-25% aqueous ammonia

[1285] D2 175:22:3 (v / v / v) dichloromethane-methanol-25% aqueous ammonia DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1286] D3 275:22:3 (v / v / v) dichloromethane-methanol-25% aqueous ammonia mixture

[1287] DIO 975:22:3 (v / v / v) dichloromethane-methanol-25% aqueous ammonia mixture

[1288] D20 1975:22:3 (v / v / v) dichloromethane-methanol-25% aqueous ammonia mixture

[1289] DCM dichloromethane (CAS: 75-09-2)

[1290] DIC N,]\ -diisopropylcarbodiimide (CAS: 693-13-0)

[1291] DIPEA A, A-diisopropylethylamine (CAS: 7087-68-5)

[1292] DLS dynamic light scattering

[1293] DMAP 4-dimethylaminopyridine (CAS: 1122-58-3)

[1294] DMEM Dulbecco's modified medium

[1295] DMF dimethylformamide (CAS: 68-12-2)

[1296] DMF-d7 deuterated dimethylformamide (CAS: 4472-41-7)

[1297] DMSO-d6 deuterated dimethyl sulfoxide (CAS: 2206-27-1)

[1298] DNA deoxyribonucleic acid

[1299] EE encapsulation efficiency

[1300] eq. equivalent(s)

[1301] ESI electrospray ionization

[1302] Et ethyl

[1303] EtOAc ethylacetate (CAS: 141-78-6) DTS Ref.: 41089.BTL.P110PC December 19, 2025 ESI electrospray ionization

[1304] F 30:1 (v / v) isopropanol-25% aqueoues ammonia

[1305] F10 30: 1:279 (v / v / v) isopropanol-25% aqueous ammonia-cyclohexane mixture F20 30: 1: 124 (v / v / v) isopropanol-25% aqueous ammonia-cyclohexane mixture F40 60:2:93 (v / v / v) isopropanol-25% aqueous ammonia-cyclohexane mixture F60 90:3:62 (v / v / v) isopropanol-25% aqueous ammonia-cyclohexane mixture F80 120:4:31 (v / v / v) isopropanol-25% aqueous ammonia-cyclohexane mixture F100 30:1 (v / v) isopropanol-25% aqueous ammonia mixture

[1306] FBS fetal bovine serum

[1307] g gram

[1308] (g) gaseous

[1309] h hour

[1310] HPLC high-performance liquid chromatography

[1311] HRMS high resolution mass spectrometry

[1312] IPA 2-propanol

[1313] zPrOAc isopropyl acetate (CAS: 108-21-4)

[1314] IU International Units

[1315] L liter

[1316] LC lipid composition

[1317] LNP lipid nanoparticle DTS Ref.: 41089.BTL.P110PC December 19, 2025 LYM lymphocytes

[1318] Ltd. Limited

[1319] mbar millibar

[1320] min minute(s)

[1321] mmol millimole

[1322] M molar concentration (mol-dm’3)

[1323] MHz megahertz

[1324] Me methyl

[1325] mM millimolar concentration (mmol. dm'3)

[1326] m / z mass-to-charge ratio

[1327] MeCN acetonitrile (CAS: 75-05-8)

[1328] MEM minimum essential medium

[1329] mRNA messenger ribonucleic acid

[1330] MS mass spectrometry

[1331] n nano

[1332] N: P Nitrogen-to-Phosphorus ratio

[1333] NA nucleic acid

[1334] ND not determined

[1335] NEU neutrophils

[1336] NMR nuclear magnetic resonance DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1337] No. number

[1338] PBS phosphate-buffered saline

[1339] PCR polymerase chain reaction

[1340] PDI polydispersity index

[1341] PEG polyethylene glycol

[1342] Ph phenyl

[1343] ppm parts per million

[1344] psi pound per square inch

[1345] PTFE polytetrafluoroethylene (CAS: 9002-84-0)

[1346] PVDF polyvinylidene fluoride (CAS: 24937-79-9)

[1347] R / retardation factor

[1348] RNA ribonucleic acid

[1349] RT room temperature

[1350] RT-PCR reverse transcription polymerase chain reaction

[1351] SD standard deviation

[1352] Selectfluor® A-chloromethyl-N'-fluorotriethylenediammonium

[1353] bis (tetrafluoroborate)

[1354] SEQ. sequence

[1355] T3P propanephosphonic acid anhydride (CAS: 68957-94-8)

[1356] TCE 1,1,2,2-tetrachloroethane (CAS: 79-34-5) DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1357] tert- tertiary

[1358] Tf triflate

[1359] TFA trifluoracetic acid (CAS: 76-05-1)

[1360] TFAA trifluoroacetanhydride (CAS: 407-25-0)

[1361] TIC total ion chromatogram

[1362] TLC thin layer chromatography

[1363] TMS tetramethylsilane

[1364] TNS 2-(p-toluidino)-6-napthalene sulfonic acid (CAS: 53313-85-2)

[1365] Tris tris(hydroxymethyl)aminomethane

[1366] UPLC ultra performance liquid chromatography

[1367] v / v volume to volume ratio

[1368] vac vacuum

[1369] WBS white blood cells

[1370] w / w weight to weight ratio

[1371]

[0274] Compound of Formula I may be prepared from commercially available materials according to the procedures illustrated in Schemes 1-60.

[1372]

[0275] The following intermediates may be employed in at least one of Schemes 1-60 below. The following intermediates A1-A22 may be prepared according to specific examples, as shown below. The intermediates have A1-A22 notations, along with internal notation. The notations Al- A22 are used for description of Schemes 1-60. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1373] AMINES A1 - A19

[1374] A DA <0)500 fX A1 J \ / X / xZ\ / \ZXzNADA‘.)0500BX A? I X / X / X^X / X / XzN N M2 ADA<)(J5005X A.5 XZX / X / XZXzXz0-xXXxX NH2ADA305034X = A4 X / \ / \ / X / X / \| / Xz%zX / x / x / X^N:x / X / XzNADA305035X - A5 zX / XZX / \ / X / \z N ^ / x / x^ « t2ADA‘)0503l> X AO XZ\ / X / X|MwX / XzNH2 ADA905084X = A7 / XZX / XzX / ^ xx. / x^xx^^^N HaADAM5085X A3 X / X / X / ^ " - X ~ X „. ',NH_ ADA9050 / 3X - A9 / X / x / vx / xy'<x..-'

[1375]

[1376] DTS Ref.: 41089.BTL.P110PC December 19, 2025 ADA901834X - A10 1

[1377]

[1378] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1379] ADA901880X = A16

[1380] O. N.

[1381] NH,

[1382]

[1383] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1384] ADA901770X = A17

[1385] ‘ " ■ ' 'S ' - NH;

[1386] ADA901884X A18

[1387] ADA90186KX A19

[1388] CARBOXYLIC ACID A20

[1389] ADA901832X = A20

[1390] HALOGENIDE A21

[1391] ADA901822X = A21

[1392] ALCOHOL A22

[1393] ADA901819X = A22

[1394]

[1395]

[0276] The following schemes may be employed in preparation of the compounds of Formula I or

[1396]

[1397] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1398]

[0277] The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of some compounds of the present disclosure. Reactions leading to some compounds of the present disclosure may be summarized by general schemes 1 to 60 below. The variables in the schemes (e.g. Y, R etc.) may be as defined herein. Person skilled in the art will note that throughout the schemes the order of certain steps may be changed, such as the introduction or removal, or introduction and removal, of a protecting group. Person skilled in the art will note that, during the reaction sequences and synthetic schemes described herein, the order of certain steps may be changed, such as the introduction or removal, or the introduction and removal, of protecting groups. One of ordinary skill in the art will recognize that certain groups may require protection from the reaction conditions via the use of protecting groups. Protecting groups may also be used to differentiate similar functional groups in molecules. A list of protecting groups and how to introduce and remove these groups can be found in Greene, T. W., Wuts, P. G. M., Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999.

[1399]

[0278] In the reaction schemes described herein, multiple stereoisomers may be produced. When no particular stereoisomer is indicated, it is understood to mean all possible stereoisomers that could be produced from the reaction. A person of ordinary skill in the art will recognize that the reactions can be optimized to give one isomer preferentially and new schemes may be devised to produce a single isomer. If mixtures are produced, techniques such as preparative thin layer chromatography, preparative HPLC, preparative chiral HPLC, preparative SFC, and combinations thereof, may be used to separate the isomers. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1400] SCHEME 1

[1401] ADA90 MITOX

[1402] step?

[1403] O j | | (>

[1404] R-' Y'-K 1i o' ’hL■*;- N H NH. L.R3K HI A II

[1405] step 4

[1406]

[1407]

[0279] As illustrated in Scheme 1 above, in step 1 acid ADA905030X reacts with thionyl chloride to afford presumably an intermediate including three carboxylic acid chlorides, which then reacts with DIPEA and benzyl alcohol to afford presumably an intermediate containing one carboxylic acid benzyl ester and two carboxylic acid chlorides. This intermediate then reacts with amine Al - A19 to afford amide I. The step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of benzyl alcohol at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1408]

[0280] In step 2, amide I reacts with H2to afford acid II The step 2 may take place in the presence of catalyst (Pd / C) and in an organic solvent (e.g. mixture of methanol and EtOAc) at room temperature.

[1409]

[0281] In step 3, acid II reacts with thionyl chloride to afford presumably an intermediate containing two amides and one carboxylic acid chloride, which then reacts with ammonia to afford amide HI. The step 3 may take place in an organic solvent (e.g. dry DCM) at room temperature and after addition of ammonia at 0 °C.

[1410]

[0282] In step 4, the amide HI reacts with DIPEA and TFAA to afford nitrile TV. The step 4 may take place in an organic solvent (e.g. DCM) at room temperature.

[1411]

[0283] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The step 1 and step 3 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1412] SCHEME 2

[1413] .0! - ■ " COOttsteP2r RY' R mm p,bADA905030X

[1414] V ADA90181 / X

[1415] 3

[1416] o | / 1 nn1 I J ° 1' flOY - ■ ™-Y * fi l; ' HN,< R*M1. \ R -

[1417]

[1418]

[0284] As illustrated in Scheme 2 above, in step 1, acid ADA905030X reacts with thionyl chloride to afford presumably an intermediate containing three carboxylic acid chlorides, which then reacts with adamantanol and DIPEA to afford presumably an intermediate containing one carboxylic acid adamantyl ester and two carboxylic acid chlorides. The intermediate then reacts with water to afford ester ADA901817X. The step 1 may take place in an organic solvent (e.g. DMF, dioxane) at temperature of 70 °C and after addition of adamantanol at room temperature.

[1419]

[0285] In step 2, ester ADA901817X reacts with thionyl chloride to afford presumably an intermediate containing one carboxylic acid adamantyl ester and two carboxylic acid chlorides, which then reacts with an amine Al - A19 to afford amide V. The step 2 may take place in an DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1420] organic solvent (e.g. DMF) at temperature of 70 °C and after addition of amine at room temperature.

[1421]

[0286] In step 3, amide V reacts with TfSOH to afford acid II. The step 3 may take place in organic solvent (e.g. DCM) at 0 °C, allowing then the temperature to increase from 0 °C to room temperature.

[1422]

[0287] In step 4, acid II reacts with thionyl chloride to afford presumably an intermediate containing two amides and one carboxylic acid chloride, which then reacts with ammonia to afford amide III. The step 4 may take place in an organic solvent (e.g. DCM) in the presence of catalyst (e.g. DMF) at room temperature and after addition of ammonia at 0 °C.

[1423]

[0288] In step 5, amide III reacts with TFAA and DIPEA to afford nitrile IV. The step 5 may take place in an organic solvent (e.g. DCM) at room temperature.

[1424]

[0289] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The step 1 and step 2 may take place in one flask without any purification or analysis.

[1425] SCHEME 3

[1426]

[1427] \ 1 VII

[1428]

[0290] In Scheme 3 above in step 1, acid VI reacts with thionyl chloride to afford presumably an intermediate containing two carboxylic acid chlorides, which then reacts with an amine Al - A19 and DIPEA to afford amide VII. The step 1 may take place in organic solvent (e.g. TCE) in the presence of a catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1429]

[0291] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The entirety of scheme 3 may take place in one flask without any purification or analysis.

[1430] SCHEME 4

[1431] *cj j0A -ctOl - ' -CUOh ‘~F hN. y. ' f R‘

[1432]

[1433] ADA9O5O3UX Will K

[1434]

[0292] In Scheme 4 above, in step 1, acid ADA905030X reacts with selectfluor® and AgNCh to afford acid VIII. The step 1 may take place in a solvent (e.g. mixture of Me2CO and water) at a temperature of 55 °C.

[1435]

[0293] In step 2, acid VIII reacts with an amine Al -Al 9, T3P and DIPEA to afford amide IX. The step 2 may take place in an organic solvent (e.g. TCE) at room temperature.

[1436] SCHEME S

[1437] | Mep 1 '4° slop ' / N C [• - y I M - {■ ' ' 7 •| (N y, - Hb. y2 J. x M N.K. XIIr.k

[1438]

[1439]

[0294] In Scheme 5 above, in step 1, acid X reacts with an amine Al - A19, T3P and DIPEA to afford amide XI. The step 1 may take place in an organic solvent (e.g. mixture of DMF and DCM) at room temperature.

[1440]

[0295] In step 2, amide XI reacts with halogenide A21, 2,6-di- / c / 7-butylpyridine, and AgOTf to afford amide XII. The second step may take place in an organic solvent (e.g. DCM) at 0 °C followed by an increase of the temperature to room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1441] SCHEME 6

[1442]

[1443]

[0296] In Scheme 6 above, in step 1, acid XIII reacts with thionyl chloride to afford presumably an intermediate containing four carboxylic acid chlorides. This intermediate then reacts with benzyl alcohol and DIPEA to afford presumably an intermediate containing two carboxylic acid chlorides and two carboxylic acid benzyl esters. This intermediate then reacts with an amine Al - A19 to afford amide XIV. The step 1 may take place in an organic solvent (e.g. TCE) in the DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1444] presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of benzyl alcohol at room temperature.

[1445]

[0297] In step 2, amide XIV reacts with H2 to afford acid XV. The step 2 may take place in an organic solvent (e.g. mixture of EtOAc and MeOH) in the presence of catalyst (e.g. 10% Pd / C) at room temperature.

[1446]

[0298] In step 3, acid XV reacts with thionyl chloride to afford presumably an intermediate containing two amides and two carboxylic acid chlorides, which then reacts with ammonia to afford amide XVI. The step 3 may take place in an organic solvent (e.g. DCM) in the presence of catalyst (e.g. DMF) at room temperature and after addition of ammonia at 0 °C.

[1447]

[0299] In step 4, amide XVI reacts with DIPEA and TFAA to afford nitrile XVII. The step 4 may take place in an organic solvent (e.g. DCM) at room temperature.

[1448]

[0300] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The step 1 may take place in one flask without any purification or analysis.

[1449] SCHEME 7

[1450]

[1451]

[0301] In Scheme 7 above, in step 1, acid A20 reacts with thionyl chloride to afford presumably an intermediate containing carboxylic acid chloride, which then reacts with amine l,3-bis(aminomethyl)adamantane or 1,3 -diaminoadamantane and DIPEA to afford amide XVIII.

[1452] The step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1453]

[0302] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The entirety of scheme 7 may take place in one flask without any purification or analysis.

[1454] SCHEME S

[1455] step 4

[1456] if

[1457] R4

[1458]

[1459] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1460]

[0303] In Scheme 8 above, in step 1, acid XIX reacts with BOC2O and NaHCO3to afford Boc-protected amine ADA901826X. The step 1 may take place in an organic solvent (e.g. aqueous dioxane) at a temperature of 50 °C.

[1461]

[0304] In step 2, Boc-protected amine ADA901826X then reacts with an amine Al - A19, T3P, and DIPEA to afford amide XX. The step 2 may take place in an organic solvent (e.g. mixture of DMF and DCM) at room temperature.

[1462]

[0305] In step 3, amide XX reacts with HC1 and dioxane to afford amide XXI. The step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1463]

[0306] In step 4, amide XXI reacts with acid A20, T3P, and DIPEA to afford compound XXII. The step 4 may take place in an organic solvent (e.g. mixture of DMF and DCM) at room temperature.

[1464] SCHEME 9

[1465] ADA901816X stop 1 HOOi.k° 1| Iui 11( 10! 11 ADA905030X step 2 ADA901878X

[1466] v H ’1O- * >■ ' erowf lO ADA901875X step 4 u HO / OH

[1467] ADAMW9X

[1468]

[1469] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1470]

[0307] In Scheme 9 above, in step 1, acid ADA905030X reacts with thionyl chloride to afford presumably an intermediate containing three carboxylic acid chlorides, which then reacts with adamantanol and DIPEA to afford presumably an intermediate containing two carboxylic acid adamantyl esters and carboxylic acid chloride. This intermediate then reacts with water to afford acid ADA901816X. The step 1 may take place in an organic solvent (e.g. mixture of dioxane and TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of water at room temperature.

[1471]

[0308] In step 2, acid ADA901816X reacts with thionyl chloride to afford presumably an intermediate containing two carboxylic acid adamantyl esters and one carboxylic acid chloride, which then reacts with ammonia to afford amide ADA901875X. The step 2 may take place in an organic solvent (e.g. DCM) in the presence of catalyst (e.g. DMF) at room temperature and after addition of ammonia at 0 °C.

[1472]

[0309] In step 3, amide ADA901875X reacts with TFAA and DIPEA to afford nitrile ADA901878X.

[1473] The step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1474]

[0310] In step 4, nitrile ADA901878X reacts with TFA to afford acid ADA901879X. The step 4 may take place in an organic solvent (anisole) at room temperature.

[1475]

[0311] In step 5, acid ADA901879X reacts with an amine Al - A19, T3P and DIPEA to afford amide TV. The step 5 may take place in an organic solvent (e.g. DCM) at room temperature.

[1476]

[0312] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The step 1 and the step 2 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1477] SCHEME 10

[1478] ADA901H16X

[1479] •«

[1480] ADA9U5U30X step 2 AOA9018 / 8X v V * / i 0ercw0ADA90W5X

[1481] HO J OH

[1482] UkNH

[1483]

[1484] Will XXIX

[1485]

[0313] In Scheme 10 above, in step 1, acid ADA905030X reacts with thionyl chloride to afford presumably an intermediate containing three carboxylic acid chlorides, which then reacts with adamantanol and DIPEA to afford presumably an intermediate containing two carboxylic acid adamantyl esters and carboxylic acid chloride. This intermediate then reacts with water to afford acid ADA901816X. The step 1 may take place in an organic solvent (e.g. mixture of dioxane and TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of water at room temperature.

[1486]

[0314] In step 2 acid ADA901816X reacts with thionyl chloride to afford presumably an intermediate containing two carboxylic acid adamantyl esters and one carboxylic acid chloride, which then DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1487] reacts with ammonia to afford amide ADA901875X. The step 2 may take place in an organic solvent (e.g. DCM) in the presence of catalyst (e.g. DMF) at room temperature and after addition of ammonia at 0 °C.

[1488]

[0315] In step 3, ADA901875X reacts with TFAA and DIPEA to afford nitrile ADA901878X. The step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1489]

[0316] In step 4, nitrile ADA901878X reacts with sulfuric acid to afford acid XXIII. The step 4 may take place in an organic solvent (e.g. DCM) at room temperature.

[1490]

[0317] In step 5, acid XIII reacts with thionyl chloride to afford presumably an intermediate containing one amide and two carboxylic acid chlorides, which then reacts with an amine Al - Al 9 and DIPEA to afford amide XXIV. The step 5 may take place in an organic solvent (e.g. TCE) at room temperature.

[1491]

[0318] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It is difficult to separate and / or analyze the intermediates. The step 1 and the step 5 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1492] SCHEME 11

[1493] step 1

[1494] XXV

[1495] step 2

[1496] XXVIII

[1497]

[1498]

[0319] In scheme 11 above, in step 1 compound XXV may react with 1 -bromododecane to afford product XXVI. Step 1 may take place in an organic solvent (e.g. mixture of MeCN and EtOAc in a ratio of 6: 1) in the presence of a base (e.g. K2CO3) at a temperature of 55 °C.

[1499]

[0320] In step 2, Boc-protected amine XXVI may react with HCl in 1,4-dioxane to afford amine XXVII. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1500]

[0321] In step 3, acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XXVII and DIPEA to afford amide XXIX. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1501]

[0322] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 11 may take place in one flask without any purification or analysis.

[1502] SCHEME 12

[1503] XXXI

[1504] step 2

[1505]

[1506]

[0323] In scheme 12 above, in step 1 compound XXX may react with 1 -bromododecane to afford product XXXI. Step 1 may take place in an organic solvent (e.g. mixture of MeCN and EtOAc in a ratio of 6: 1) in the presence of a base (e.g. K2CO3) at a temperature of 55 °C.

[1507]

[0324] In step 2, Boc-protected amine XXXI may react with HCl in 1,4-dioxane to afford amine XXXII. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1508]

[0325] In step 3, acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XXXII and DIPEA to afford DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1509] amide XXXIII. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature.

[1510]

[0326] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 12 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1511]

[1512] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1513]

[0327] In scheme 13 above, in step 1 compound XXXIV may react with (Z)-9-bromonon-3-ene to afford product XXXV. Step 1 may take place in an organic solvent (e.g. mixture of MeCN and EtOAc in a ratio of 6:1) in the presence of a base (e.g. K₂CO₃) at a temperature of 55 °C.

[1514]

[0328] In step 2 compound XXXV may react with HCl in 1,4-dioxane to afford product XXXVI. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1515]

[0329] In step 3, acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XXXVI and DIPEA to afford amide XXXVII. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature.

[1516]

[0330] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 13 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1517] SCHEME 14

[1518]

[1519]

[0331] In scheme 14 above, in step 1 compound XXXIV may react with 1 -bromo-2-octyne to afford product XXXVIII. Step 1 may take place in an organic solvent (e.g. mixture of MeCN and EtOAc in a ratio of 6: 1) in the presence of a base (e.g. K₂CO₃) at a temperature of 55 °C.

[1520]

[0332] In step 2 compound XXXVIII may react with HCl in 1,4-dioxane to afford amine XXXIX.

[1521] Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1522]

[0333] In step 3 acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XXXIX and DIPEA to afford amide XL. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1523]

[0334] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 14 may take place in one flask without any purification or analysis.

[1524]

[1525]

[0335] In scheme 15 above, in step 1 compound XXXIV may react with 1 -bromooctacosane to afford product XLI. Step 1 may take place in an organic solvent (e.g. cyclohexane) in the presence of a base (e.g. K₂CO₃) at a temperature of 55 °C.

[1526]

[0336] In step 2 compound XLI may react with HCl in 1,4-dioxane to afford amine XLII. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1527]

[0337] In step 3 acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XLII and DIPEA to afford amide DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1528] XLIII Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature.

[1529]

[0338] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 15 may take place in one flask without any purification or analysis.

[1530] SCHEME 16

[1531] H2N

[1532]

[1533]

[0339] In scheme 16 above, in step 1 compound XLIV may react with 1 -bromododecane to afford product XLV. Step 1 may take place in an organic solvent (e.g. mixture of MeCN and EtOAc in a ratio of 6: 1) in the presence of a base (e.g. K₂CO₃) at a temperature of 55 °C.

[1534]

[0340] In step 2 compound XLV may react with HCl in 1,4-dioxane to afford amine XLVI. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1535]

[0341] In step 3 acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides, which then may react with amine XLII and DIPEA to afford amide XL VII. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of amine at room temperature.

[1536]

[0342] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 16 may take place in one flask without any purification or analysis.

[1537] step 1

[1538]

[1539]

[0343] In scheme 17 above, in step 1 compound ADA000012L may react with thiation agent (e.g.

[1540] 2,4-bis(4-methoxyphenyl)-l,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson's reagent)) to afford thionoester XL VIII. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of 60 °C.

[1541]

[0344] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 17 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1542] SCHEME 18

[1543] ADA901822X

[1544]

[1545]

[0345] In scheme 18 above, in step 1 compound ADA901822X may react with hydrosulfide (e.g.

[1546] sodium hydrosulfide) to afford thiol derivative XLIX. Step 1 may take place in an organic solvent (e.g. EtOH) at a temperature of 78 °C.

[1547]

[0346] In step 2, adamantane- 1,3, 5 -tricarboxylic acid XXVIII may react with thionyl chloride in presence of catalytic amount of tertiary amide (e.g. DMF, DMAC) to afford an intermediate containing two carboxlic acid chlorides, wich may then react with thiol derivative XLIX in presence of organic base (e.g. DIPEA, Et₃N), to afford thiolester L. Step 2 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at temperature of 70 °C and after addition of thiol derivative at room temperature.

[1548]

[0347] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 18 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1549] SCHEME 19

[1550] ADA901822X

[1551]

[1552]

[0348] In scheme 19 above, in step 1 1,3 -dibromoadamantane (LI) may react with magnesium to afford Grignard reagent (adamant-1, 3-diyldimagnesium dibromide), which may afterwards react with CS₂. Resulting intermediate may react with ADA901822X to afford product LII. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of 40 °C.

[1553]

[0349] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 19 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1554]

[1555]

[0350] In scheme 20 above, in step 1, carboxylic acid LIII (7-(didodecylamino)heptanoic acid) may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with 1,3-adamantanediol LIV in presence of organic base (e.g. DIPEA, Et₃N), to afford ester LV. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of 1,3-adamantanediol at room temperature.

[1556]

[0351] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 20 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1557] SCHEME 21

[1558]

[1559]

[0352] In scheme 21 above, in step 1 1,3-bis(hydroxymethyl)adamantane (LVI) may react with XLIX in presence of tertiary phosphine (e.g. triphenylphosphine) and azo-disubstituted derivative (e.g. diisopropyl azodicarboxylate) to afford thioether LVII. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of 0 °C during addition of reagents and at room temperature afterwards.

[1560]

[0353] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 21 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1561]

[1562]

[0354] In scheme 22 above, in step 1, carboxylic acid LIII (7-(didodecylamino)heptanoic acid) may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with adamantane- 1,3 -dithiol LVIII in presence of organic base (e.g. DIPEA, Et₃N), to afford thiolester LIX. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of adamantane- 1,3-dithiol at room temperature.

[1563]

[0355] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 22 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1564]

[1565] 10

[0356] In scheme 23 above, in step 1, 1,3 -dibromoadamantane LI may react with an excess of hydrazine hydrate to afford bis(hydrazinyl)adamantane derivative LX.

[1566]

[0357] In step 2, LX may react with bromide ADA901822X in presence of organolithium reagent (e.g. nBuLi), to afford substituted hydrazine LXI. Step 2 may take place in an organic solvent (e.g. THF) at a temperature of -78 °C and after addition of bromide ADA901822X at room temperature.

[1567]

[0358] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 23 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1568] step 1

[1569]

[1570] 10

[0359] In scheme 24 above, in step 1, carboxylic acid LIII (7-(didodecylamino)heptanoic acid) may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with bis(hydrazinyl)adamantane derivative LX in presence of organic base (e.g. DIPEA, Et₃N), to afford hydrazide LXII. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of bis(hydrazinyl)adamantane derivative at room temperature.

[1571]

[0360] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 24 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1572] SCHEME 25

[1573]

[1574]

[0361] In scheme 25 above, in step 1, 1 -bromoadamantane LXIII may react with a vinyl bromide in presence of aluminium bromide to afford an intermediate containing two 2,2-dibromoethyl groups. This intermediate may react with a strong base (e.g. KOH) to afford 1,3- diethynyladamantane LXIV. Step 1 may take place in an organic solvent (e.g. DCM) at a temperature of -60 °C during addition of vinyl bromide, at room temperature during stirring and then in a high boiling organic solvent (e.g. DMSO) at a temperature of 100 °C after addition of a base.

[1575]

[0362] In step 2, LXIV may react with bromide ADA901822X in presence of organolithium reagent (e.g. nBuLi), to afford product LXV containing two disubstituted alkynyl groups. Step 2 may take place in an organic solvent (e.g. THF) at a temperature of -78 °C and after addition of bromide ADA901822X at a room temperature.

[1576]

[0363] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 25 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1577] SCHEME 26

[1578]

[1579]

[0364] In scheme 26 above, in step 1, adamantane- 1,3 -di carbonitrile LXVI may react with a tin(II) chloride in presence of hydrogen chloride followed by treatment with water to afford adamantane- 1,3- dicarbaldehyde LXVII. Step 1 may take place in an organic solvent (e.g. Et₂O) at a temperature of 0 °C and at a temperature of 60 °C after addition of water.

[1580]

[0365] In step 2, ADA901822X may react with trisubstituted phosphine (e.g. Ph₃P) to afford phosphonium salt LXVIII. Step 2 may take place in an organic solvent (e.g. toluene) at a temperature of reflux.

[1581]

[0366] In step 3, phosphonium salt LXVIII may react with strong base (e.g. potassium bis(trimethylsilyl)amide) to afford an intermediate containing ylide derivative. This intermediate may react with the adamantane-l,3-dicarbaldehyde LXVII to afford product LXIX containing two disubstituted alkenyl groups. Step 3 may take place in an organic solvent (e.g. THF) at a temperature of -78 °C and after addition of dicarbaldehyde LXVII at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1582]

[0367] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 26 may take place in one flask without any purification or analysis.

[1583] SCHEME 27

[1584]

[1585]

[0368] In scheme 27 above, in step 1, alcohol derivative ADA901819X may react with a hypervalent iodine derivative (e.g. l,l,l-tris(acetyloxy)-l,l-dihydro-l,2-benziodoxol-3-(lH)-one (Dess- Martin periodinane)) to afford a carbaldehyde derivative LXX. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1586]

[0369] In step 2, LXX may react with diamine LXXI in presence of molecular sieves (e.g. 4 Å type), to afford product LXXII containing two imino groups. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature.

[1587]

[0370] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 27 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1588]

[1589]

[0371] In scheme 28 above, in step 1, adamantane- 1,3 -di carbaldehyde LXVII may react with amine ADA901749X in presence of molecular sieves (e.g. 4 Å type), to afford product LXXIII containing two imino groups. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1590]

[0372] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 28 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1591] SCHEME 29

[1592] ADA901819X

[1593]

[1594]

[0373] In scheme 29 above, in step 1, alcohol derivative ADA901819X may react with a hypervalent iodine derivative (e.g. l,l,l-tris(acetyloxy)-l,l-dihydro-l,2-benziodoxol-3-(lH)-one (Dess- Martin periodinane)) to afford a carbaldehyde derivative LXXIV. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1595]

[0374] In step 2, LXXIV may react with bis(hydrazinyl)adamantane derivative LX in presence of organic acid (e.g. acetic acid), to afford product LXXV containing two hydrazone groups. Step 2 may take place in an organic solvent (e.g. MeOH) at a temperature of reflux.

[1596]

[0375] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 29 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1597] SCHEME 30

[1598]

[1599]

[0376] In scheme 30 above, in step 1, LXVII may react with hydrazine derivative LXXVI in presence of organic acid (e.g. acetic acid), to afford product LXXVII containing two hydrazone groups. Step 1 may take place in an organic solvent (e.g. MeOH) at a temperature of reflux.

[1600]

[0377] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 30 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1601] SCHEME 31

[1602]

[1603]

[0378] In scheme 31 above, in step 1, amine ADA901834X may react with 1,1'- thiocarbonyldiimidazole to afford an intermediate containing (thiocarbonyl)imidazolide moiety. This intermediate may react with adamantane- 1,3 -diol LIV in presence of organic base (e.g. DIPEA, Et₃N), to afford thiocarbamate LXXVIII. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of reflux.

[1604]

[0379] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 31 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1605] SCHEME 32

[1606]

[1607]

[0380] In scheme 32 above, in step 1, alcohol LXXIX may react with 1,1'-thiocarbonyldiimidazole to afford an intermediate containing (thiocarbonyl)imidazolide moiety. This intermediate may react with adamantane- 1,3 -diamine LXXI in presence of organic base (e.g. DIPEA, Et₃N), to afford thiocarbamate LXXX. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of reflux.

[1608]

[0381] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 32 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1609] SCHEME 33

[1610]

[1611]

[0382] In scheme 33 above, in step 1, amine ADA901834X may react with 1,1'- thiocarbonyldiimidazole to afford an intermediate containing (thiocarbonyl)imidazolide moiety. This intermediate may react with adamantane- 1,3 -diamine LXXI in presence of organic base (e.g. DIPEA, Et₃N), to afford thiourea LXXXI. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of reflux.

[1612]

[0383] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 33 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1613] step 1

[1614]

[1615] 10

[0384] In scheme 34 above, in step 1, bromide ADA901822X may react with magnesium metal to afford an intermediate alkylmagnesium bromide. This intermediate may react with adamantane- 1,3 -dicarbonitrile LXVI to afford ketone LXXXII. Step 1 may take place in an organic solvent (e.g. THF) at a temperature of reflux.

[1616]

[0385] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 34 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1617] SCHEME 35

[1618] 10

[1619] step 1

[1620]

[1621] 10

[0386] In scheme 35 above, in step 1, ketone LXXXIII may react with reducing agent (e.g. sodium borohydride, (NaBH₄)) to afford secondary alcohol LXXXIV. Step 1 may take place in an organic solvent (e.g. EtOH) at room temperature.

[1622]

[0387] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 35 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1623] SCHEME 36

[1624]

[1625]

[0388] In scheme 36 above, in step 1, alkyne LXV may react with reducing agent (e.g. palladium on carbon, (Pd / C)) to afford alkane LXXXV. Step 1 may take place in an organic solvent (e.g. EtOH) at room temperature.

[1626]

[0389] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 36 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1627] SCHEME 37

[1628] HOOC LXXXVII LXXXVI

[1629] step 3

[1630]

[1631] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1632]

[0390] In scheme 37 above, in step 1, bromoalcohol LXXXVI may react with acid LXXXVII, DIC and DMAP to afford bromoester LXXXVIII. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1633]

[0391] In step 2, LXXXVIII may react with amine XXIV in presence of base (e.g. K₂CO₃), to afford trisubstituted amine LXXXIX. Step 2 may take place in an organic solvent (e.g. MeCN) at a temperature of 55 °C.

[1634]

[0392] In step 3, LXXXIX may be deprotected in presence of acid (e.g. HCl in 1,4-dioxane), to afford diamine XC. Step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1635]

[0393] In step 4, adamantane- 1,3 -dicarboxylic acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides. This intermediate may react with diamine XC in presence of organic base (e.g. DIPEA, Et₃N), to afford amide XCI. Step 4 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of diamine at room temperature.

[1636]

[0394] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 37 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1637] SCHEME 38

[1638]

[1639] XCV

[1640]

[0395] In scheme 38 above, in step 1, bromide derivative XCII may react with amine XXIV in presence of base (e.g. K₂CO₃), to afford trisubstituted amine XCIII. Step 1 may take place in an organic solvent (e.g. MeCN) at a temperature of 55 °C.

[1641]

[0396] In step 2, XCIII may be deprotected in presence of acid (e.g. HCl in 1,4-dioxane), to afford diamine XCIV. Step 2 may take place in an organic solvent (e.g. DCM) at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1642]

[0397] In step 3, adamantane- 1,3 -dicarboxylic acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides. This intermediate may react with diamine XCIV in presence of organic base (e.g. DIPEA, Et₃N), to afford amide XCV. Step 3 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of diamine at a room temperature.

[1643]

[0398] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 38 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025 SCHEME 39

[1644] Br3COOH + H2N XCVII XCVI HOOC

[1645]

[1646] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1647]

[0399] In scheme 39 above, in step 1, bromoacid XCVI may react with alcohol XCVII, DIC and DMAP to afford bromoamide XCVIII. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1648]

[0400] In step 2, XCVIII may react with amine XXIV in presence of base (e.g. K2CO3), to afford trisubstituted amine XCIX. Step 2 may take place in an organic solvent (e.g. MeCN) at a temperature of 55 °C.

[1649]

[0401] In step 3, XCIX may be deprotected in presence of acid (e.g. HCl in 1,4-dioxane), to afford diamine C. Step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1650]

[0402] In step 4, adamantane- 1,3 -dicarboxylic acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides. This intermediate may react with diamine C in presence of organic base (e.g. DIPEA, Et3N), to afford amide CI. Step 4 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of diamine at a room temperature.

[1651]

[0403] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 39 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1652] SCHEME 40

[1653] step 3

[1654]

[1655] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1656]

[0404] In scheme 40 above, in step 1, amine derivative CII may react with acid CIII, DIC and DMAP to afford amide CIV. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1657]

[0405] In step 2, CIV may react with amine XXIV in presence of base (e.g. K2CO3), to afford trisubstituted amine CV. Step 2 may take place in an organic solvent (e.g. MeCN) at a temperature of 55 °C.

[1658]

[0406] In step 3, CV may be deprotected in presence of acid (e.g. HCl in 1,4-dioxane), to afford diamine CVI. Step 3 may take place in an organic solvent (e.g. DCM) at room temperature.

[1659]

[0407] In step 4, adamantane- 1,3 -dicarboxylic acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides. This intermediate may react with diamine CVI in presence of organic base (e.g. DIPEA, Et3N), to afford amide CVII. Step 4 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of diamine at room temperature.

[1660]

[0408] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 40 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025 SCHEME 41

[1661]

[1662] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1663]

[0409] In scheme 41 above, in step 1, diol CVIII may react with halogenide CIX, 2,6-di-tert- butylpyridine, and AgOTf to afford alcohol CX. Step 1 may take place in an organic solvent (e.g. DCM) at 0 °C followed by an increase of the temperature to room temperature.

[1664]

[0410] In step 2, CX may react with CBr4and Ph3P to afford bromide CXI. Step 2 may take place in an organic solvent (e.g. DCM) at 0 °C followed by an increase of the temperature to room temperature.

[1665]

[0411] In step 3, CXI may react with amine XXIV in presence of base (e.g. K2CO3), to afford trisubstituted amine CXII Step 3 may take place in an organic solvent (e.g. MeCN) at a temperature of 55 °C.

[1666]

[0412] In step 4, CXII may be deprotected in presence of acid (e.g. HCl in 1,4-dioxane), to afford diamine CXIII. Step 4 may take place in an organic solvent (e.g. DCM) at room temperature.

[1667]

[0413] In step 5, adamantane- 1,3 -dicarboxylic acid XXVIII may react with thionyl chloride to afford an intermediate containing two carboxylic acid chlorides. This intermediate may react with diamine CXIII in presence of organic base (e.g. DIPEA, Et3N), to afford amide CXIV. Step 5 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of 70 °C and after addition of diamine at room temperature.

[1668]

[0414] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 41 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1669] SCHEME 42

[1670]

[1671]

[0415] In scheme 42 above, in step 1 compound CXV may react with amine ADA901822X and coupling reagent (e.g. HATU) in presence of base (e.g. Et3N) to afford amide CXVI. Step 1 may take place in an organic solvent (e.g. DMF) at room temperature.

[1672]

[0416] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 42 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1673] SCHEME 43

[1674]

[1675]

[0417] In scheme 43 above, in step 1 compound CXVII may react with amine ADA901822X and coupling reagent (e.g. HATU) in presence of base (e.g. Et3N) to afford amide CXVIII. Step 1 may take place in an organic solvent (e.g. DMF) at room temperature.

[1676]

[0418] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 43 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1677] SCHEME 44

[1678] step 1

[1679]

[1680] CXIX

[1681]

[0419] In scheme 44 above, in step 1, acid ADA901762L may react with with BH3. THF to afford alcohol CXIX. Step 1 may take place in an organic solvent (e.g. 2-methyltetrahydrofuran) at room temperature.

[1682]

[0420] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 44 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1683] SCHEME 45

[1684] step 1

[1685]

[1686] CXX

[1687]

[0421] In scheme 45 above, in step 1 acid ADA901762L may react with azide salt (e.g. NaN3) and acid (e.g. TFA) to afford amine CXX. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1688]

[0422] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 45 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1689] SCHEME 46

[1690] step 1

[1691]

[1692]

[0423] In scheme 46 above, in step 1, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with methanol in presence of organic base (e.g. DIPEA, Et3N), to afford ester CXXI. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of reflux and after addition of methanol at room temperature.

[1693]

[0424] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 46 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1694] SCHEME 47

[1695] step 1

[1696]

[1697]

[0425] In scheme 47 above, in step 1, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with ethylene glycol in presence of organic base (e.g. DIPEA, Et3N), to afford ester CXXII. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of reflux and after addition of ethylene glycol at room temperature.

[1698]

[0426] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 47 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1699] SCHEME 48

[1700]

[1701] CXXIII

[1702]

[0427] In scheme 48 above, in step 1, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with ethanolamine in presence of organic base (e.g. DIPEA, Et3N), to afford ester CXXIII Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of reflux and after addition of ethanolamine at room temperature.

[1703]

[0428] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 48 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1704] SCHEME 49

[1705]

[1706]

[0429] In scheme 49 above, in step 1, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with 3- aminopropanamide in presence of organic base (e.g. DIPEA, Et3N), to afford ester CXXIV. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of reflux and after addition of 3-aminopropanamide at room temperature.

[1707]

[0430] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 49 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1708] SCHEME 50

[1709] ADA901762L step 1

[1710]

[1711]

[0431] In scheme 50 above, in step 1, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with 1- amino-3-(dimethylamino)propane in presence of organic base (e.g. DIPEA, Et3N), to afford amide CXXV. Step 1 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1712] DMF) at a temperature of reflux and after addition of 1-amino-3-(dimethylamino)propane at room temperature.

[1713]

[0432] In step 2, amine CXXV may react with sodium 2-bromethanesulfonate to afford the product CXXVI. Step 2 may take place in an organic solvent (e.g. THF) at a temperature of reflux.

[1714]

[0433] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 50 may take place in one flask without any purification or analysis.

[1715] step 2

[1716] O CXXVII CXXVIII

[1717]

[1718]

[0434] In scheme 51 above, in step 1, ether CXXVII may react with reducing agent (e.g. palladium on charcoal under a positive pressure of hydrogen, (Pd / C)) to afford alcohol CXXVIII. Step 1 may take place in an organic solvent (e.g. EtOH) at room temperature. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1719]

[0435] In step 2, carboxylic acid ADA901762L may react with thionyl chloride to afford an intermediate containing carboxylic acid chloride. This intermediate may react with CXXVIII in presence of organic base (e.g. DIPEA, Et3N), to afford ester CXXIX Step 2 may take place in an organic solvent (e.g. TCE) in the presence of catalyst (e.g. DMF) at a temperature of reflux and after addition of CXXVIII at room temperature.

[1720]

[0436] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 51 may take place in one flask without any purification or analysis.

[1721] SCHEME 52

[1722] step 1

[1723]

[1724]

[0437] In scheme 52 above, in step 1 alcohol CXVI may react with methyliodide, 2,6-di-tert- butylpyridine, and AgOTf to afford ether CXXX. Step 1 may take place in an organic solvent (e.g. DCM) at 0 °C followed by an increase of the temperature to room temperature.

[1725]

[0438] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 52 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1726] SCHEME 53

[1727] step 1

[1728]

[1729]

[0439] In scheme 53 above, in step 1 amine CXX may react with acetyl chloride in presence of a base (e.g. DIPEA) to afford amide CXXXI. Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1730]

[0440] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 53 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1731] SCHEME 54

[1732] 10

[1733] step 1

[1734]

[1735]

[0441] In scheme 54 above, in step 1 amine CXX may react with methanesulfonyl chloride in presence of a base (e.g. DIPEA) to afford sulfonamide CXXXII Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1736]

[0442] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 54 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1737] SCHEME 55

[1738] step 1

[1739]

[1740]

[0443] In scheme 55 above, in step 1 amine CXX may react with dimethylcarbamyl chloride in presence of a base (e.g. DIPEA) to afford urea derivative CXXXIII Step 1 may take place in an organic solvent (e.g. DCM) at room temperature.

[1741]

[0444] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 55 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1742] SCHEME 56

[1743] 10

[1744] step 1

[1745]

[1746]

[0445] In scheme 56 above, in step 1 amine CXX may react with sodium dicyanamide in presence of an acid (e.g. HC1) to afford cyanoguanidine derivative CXXXIV. Step 1 may take place in an organic solvent (e.g. butan-l-ol) at a temperature of reflux.

[1747]

[0446] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 56 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1748] SCHEME 57

[1749] 10

[1750] step 1

[1751] CXXXV

[1752] step 2

[1753]

[1754]

[0447] In scheme 57 above, in step 1, amine CXX may react with formaldehyde and HCOOH to afford dimethylamine derivative CXXXV. Step 1 may take place in an organic solvent (e.g. MeOH) at a temperature of reflux. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1755]

[0448] In step 2, dimethylamine derivative CXXXV may react with 1,3-propanesultone to afford sulfonate CXXXVI. Step 2 may take place in an organic solvent (e.g. EtOAc) at room temperature.

[1756]

[0449] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 57 may take place in one flask without any purification or analysis.

[1757] SCHEME 58

[1758] 10

[1759] step 1

[1760]

[1761]

[0450] In scheme 58 above, in step 1 dimethylamine derivative CXXXV may react with acrylic acid in presence of a stabilizer (e.g. hydroquinone) to afford acid CXXXVII. Step 1 may take place in an organic solvent (e.g. DMF) at a temperature of 70 °C.

[1762]

[0451] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 58 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1763] SCHEME 59

[1764] 10

[1765]

[1766]

[0452] In scheme 59 above, in step 1 amine CXX may react with CXXXVIII (3-(dimethylamino)-4- methoxycyclobut-3-ene-l, 2-dione) to afford squareamide CXXXIX. Step 1 may take place in an organic solvent (e.g. THF) at room temperature.

[1767]

[0453] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 59 may take place in one flask without any purification or analysis. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1768] SCHEME 60

[1769] step 1

[1770] CXLI

[1771]

[1772] DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1773]

[0454] In scheme 60 above, in step 1 acid ADA901762L may react with ethylenediamine and coupling reagent (e.g. HATU) in presence of a base (e.g. Et3N) to afford aminoamide CXL Step 1 may take place in an organic solvent (e.g. DMF) at room temperature.

[1774]

[0455] In step 2, aminoamide CXL may react with formaldehyde and HCOOH to afford intermediate containing methylamine group. This intermediate may react with CXXXVIII (3- (dimethylamino)-4-methoxycyclobut-3-ene-l, 2-dione) to afford squar eamide CXLI. Step 2 may take place in an organic solvent (e.g. MeOH) at a temperature of reflux and after addition of CXXXVIII at room temperature.

[1775]

[0456] Intermediates, which are not drawn in the scheme, may be present even though they were not analyzed. It may be difficult to separate and / or analyze the intermediates. The entirety of scheme 60 may take place in one flask without any purification or analysis.

[1776]

[0457] Examples

[1777]

[0458] All reagents that are not coded and all solvents used were obtained commercially, unless otherwise specified. The NMR spectra were measured on Bruker AVANCE-600 instrument (1H at 600 MHz and13C at 150.9 MHz) with a cryoprobe in CDCl₃ or DMSO-d6 or CD₃OD or DMF- d7 at 25 °C. Spectra were referenced to solvent peak and chemical shifts recalculated to δ-scale using δ(H) = 7.26 ppm and δ(C) = 77.0 ppm for CDCl₃, δ(H) = 2.50 ppm and δ(C) = 39.52 ppm for DMSO-d6, δ(H) = 3.31 ppm and δ(C) = 49.15 ppm for CD₃OD, δ(H) = 8.03 ppm and δ(C) = 34.89 ppm for DMF-d7. Some signals of carbon atoms may be missing because of possible overlapping. Flash chromatography purifications were carried out on silica gel (particle size 40-63 pm, pore size 60A, Sigma-Aldrich) using Biotage Isolera Prime or ECOM Compact Preparative System. HR-MS spectra were obtained on an LTQ-orbitrap XL FTMS mass spectrometer (Thermo Fisher Scientific) in electrospray ionization mode. HR-MS / LR-MS (MALDI / TOF / TOF) spectra were obtained on an Ultra extreme™ mass spectrometer (Bruker Daltonics). LR-MS spectra were measured on a Q-Tof micro mass spectrometer (Waters) in electrospray ionization mode. UPLC MS spectra were obtained on a Waters Acquity H-class UPLC system.

[1778]

[0459] The UPLC-MS-CAD analysis was performed using an ultra-performance liquid chromatography system coupled to a mass spectrometer and a charged aerosol detector DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1779] (CAD). The analysis employed two mobile phases, an aqueous mobile phase C (water + 0.1% (v / v) formic acid) and an organic mobile phase D (acetonitrile / isopropanol (75:25 (v / v)) + 0.1% formic acid). For chromatographic separation, either a C18 column (ACQUITY™ Premier CSH C18 column having a particle size of 1.7 pm, VanGuard™ FIT, with dimensions of 2.1 x 100 mm) or a phenyl-hexyl column (ACQUITY™ Premier CSH Phenyl-Hexyl column having a particle size of 1.7 pm, VanGuard™ FIT, with dimensions of 2.1 x 100 mm) was used. The choice of stationary phase was adapted to the polarity and structure of compounds that were analyzed. The UPLC -MS- CAD analysis carried out under these conditions provides chromatograms of the reaction mixture with distinct peaks. Methods used for UPLC -MS-CAD analysis are described below.

[1780]

[0460] Methods for UPLC-MS-CAD:

[1781] Method A: Phenyl-hexyl column - Flow rate 0.400 ml / min - Gradient 0 min C 40 % D 60 %; 6 min C 10 % D 90%; 12 min C 10 %D 90 %, + 3 min pre-inj ection step

[1782] Method B: Phenyl-hexyl column - Flow rate 0.400 ml / min - Gradient 0 min C 95 % D 5 %; 6 min C 0 % D 100%; 12 min C 0 % D 100 %, + 3 min pre-inj ection step

[1783] Method C: C18 column - Flow rate 0.400 ml / min - Gradient 0 min C 40 % D 60 %; 6 min C 10 % D 90 %; 12 min C 10 % D 90 %, + 3 min pre-injection step

[1784] Method D: C18 column - Flow rate 0.400 ml / min - Gradient 0 min C 95 % D 5 %; 5 min C 0 % D 100%; 9 min C 0 % D 100 %, + 1 min pre-injection step

[1785] Method E: C18 column - Flow rate 0.400 ml / min - Gradient 0 min C 40 % D 60 %; 6 min C 0 % D 100%; 12 min C 0 % D 100 %, + 3 min pre-injection step

[1786]

[0461] It is noted that term “removed under vacuum on a rotary vacuum evaporator” refers to a method, which is done at 70 °C for at least 20 min while under a pressure of 20 mbar.

[1787] Example 1 - ADA905007X

[1788] / c / V-Butyl (2-(didodecylamino)ethyl)carbamate ADA905004X

[1789]

[0462] A 60mL vial equipped with a magnetic stirring crossbar and a septum cap containing a needle outlet was charged with a solution of / c / V-butyl (2-aminoethyl)carbamate (642 mg, 4.0 mmol) in DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1790] MeCN: EtOAc 6: 1 (v / v 40 mL). 1 -Bromododecane (2.5 g, 10 mmol, 2.5 eq.) and anhydrous K2CO3(5.55 g, 40.1 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 3 days. Progress of the reaction was monitored by TLC using a 50:50 (v / v) CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified via flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA905004X was obtained as a colorless oil (1.52 g, 76% yield, Ay 0.9 in mobile phase CE50 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1791] A1, A1-Didodecylethane- 1,2-diamine ADA905007X

[1792]

[0463] Boc-protected amine ADA905004X (1.5 g, 3.02 mmol) was dissolved in DCM (5 mL) in a 25 mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HCl in 1,4-dioxane (5 mL, excess) was added. The reaction mixture was stirred at room temperature overnight. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted with EtOAc and NaHCO₃ in water. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO₃ (300 mL), and the product was extracted with Et₂O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine AD A90500X was obtained asayellowish oil (1.13 g, 94% yield, R / 0.6 in mobile phase D2, detection with ninhydrin).

[1793] 'H NMR (600 MHz, CDCl3) 82.70 (t, J= 6.1 Hz, 2H), 2.44 (t, J= 5.7 Hz, 2H), 2.38 (m, 4H), 1.49 (br s, 2H), 1.41 (m, 4H), 1.26 (m, 36H), 0.87 (t, J = 7.0 Hz, 6H).

[1794] 13C NMR (151 MHz, CDCl₃) δ 57.34, 54.41, 39.93, 31.91, 29.68, 29.65, 29.64, 29.63, 29.57, 29.35, 27.54, 27.22, 22.68, 14.10. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1795] C, K;CtJy ADAW. OMX

[1796] U i

[1797] "Cr’ MeCNd tUAc

[1798] M, C tT-. / Cly:rCH Tu HCI in

[1799] 1 I di-JX. HH’ DCM H I

[1800]

[1801] " ADA90MWX

[1802] Example 2 - ADA905008X

[1803]

[0464] / c / V-Butyl (3-(didodecylamino)propyl)carbamate ADA905005X

[1804]

[0465] A 60mL vial equipped with a magnetic stirring cross-bar and a septum cap containing a needle outlet was charged with a solution of tert-butyl (3-aminopropyl)carbamate (699 mg, 4.0 mmol) in MeCN: EtOAc 6: 1 (v / v 40 mL). 1 -Bromododecane (2.5 g, 10 mmol, 2.5 eq.) and anhydrous K2CO3(5.55 g, 40.1 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 3 days. Progress of the reaction was monitored by TLC using a 50:50 (v / v) CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified via flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA905005X was obtained as a colorless oil (1.62 g, 79% yield, Ay 0.8 in mobile phase CE50 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1805] A1, Nl-Didodecy Ipropane- 1, 3 -diamine AD A905008X

[1806]

[0466] Boc-protected amine ADA905005X (1.62 g, 3.17 mmol) was dissolved in DCM (5 mL) in a 25 mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1807] in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature overnight. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted with EtOAc and NaHCO₃ in water. The solution was then poured into a 500 mL separatory funnel, diluted with saturated aqueous NaHCO₃ (300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine ADA905008X was obtained as a yellowish oil (1.16 g, 89% yield, Ay 0.5 in mobile phase D2, detection with ninhydrin).

[1808] ¹H NMR (600 MHz, CDCl₃) δ 2.73 (t, J = 6.8 Hz, 2H), 2.46 (m, 2H), 2.38 (m, 4H), 1.69 (br s, 2H), 1.59 (m, 2H), 1.42 (m, 4H), 1.28 (m, 36H), 0.88 (t, J = 7.0 Hz, 6H).

[1809] 13C NMR (151 MHz, CDCl₃) δ 54.16, 52.03, 40.94, 31.91, 30.70, 29.67, 29.66, 29.64, 29.35, 27.62, 26.92, 22.68, 14.11.

[1810] 0-,

[1811] MeCNT.lOAc (JMCH-!Knt -Br HCI in 1 4 dm. mu DCM

[1812] H l

[1813] H-JJ;1‘

[1814]

[1815] AHAHOM-OKX

[1816] Example 3 - ADA905009X

[1817] tert-Butyl (4-(didodecylamino)butyl)carbamate ADA905006X

[1818]

[0467] A 60mL vial equipped with a magnetic stirring cross-bar and a septum cap containing a needle outlet was charged with a solution of tert-butyl (4-aminobutyl)carbamate (655 mg, 4.0 mmol) in DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1819] MeCN: EtOAc 6: 1 (v / v 40 mL). 1 -Bromododecane (2.5 g, 10 mmol, 2.5 eq.) and anhydrous K2CO3(5.55 g, 40.1 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 3 days. Progress of the reaction was monitored by TLC using a 50:50 (v / v) CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified via flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA905006X was obtained as a colorless oil (1.50 g, 71% yield, Ay 0.8 in mobile phase CE50 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1820] A1, A1-Didodecylbutane- 1,4-diamine ADA905009X

[1821]

[0468] Boc-protected amine ADA905006X (1.5 g, 2.86 mmol) was dissolved in DCM (5 mL) in a 25mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature overnight. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted with EtOAc and NaHCOs in water. The solution was then poured into a 500 mL separatory funnel, diluted with saturated aqueous NaHCOs (300 mL), and the product was extracted with Et₂O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine ADA905009X was obtained as a yellowish oil (1.05 g, 86.5% yield, A / 0.5 in mobile phase D2, detection with ninhydrin).

[1822] 'H NMR (600 MHz, CDCl3) 82.97 (br s, 2H), 2.74 (m, 2H), 2.44 (m, 6H), 1.51 (m, 4H), 1.43 (m, 4H), 1.27 (m, 36H), 0.87 (t, J= 7.0 Hz, 6H).

[1823] 13C NMR(151 MHZ, CDCl3) 853.86, 53.76, 41.75, 31.90, 31.07, 29.66, 29.64, 29.63, 29.62, 29.57, 29.34, 27.61, 26.38, 24.50, 22.67, 14.10. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1824] K - C 0; ADAMMKM. X MvCN-l IOAL ss r

[1825] MCI hi 1 4 tirn. K, wu- DCM RT

[1826] HX; J

[1827]

[1828] ' • ' ll) ADA905009X

[1829] Example 4 - ADA905034X

[1830] / / 7-Butyl (5-(tridecylamino)pentyl)carbamate ADA905028X

[1831]

[0469] A 250mL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of tert-butyl (5-aminopentyl)carbamate (2.49 g, 12.4 mmol) in MeCN: EtOAc 6: 1 (v / v, 170 mL). 1 -Bromotridecane (3.0 mL, 11.7 mmol, 0.94 eq.) and anhydrous K2CO3(17.1 g, 124 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 3 nights. Progress of the reaction was monitored by TLC using a 50:50 (v / v) CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. The product of the chromatography was a dialkylated side product (Rf 0.8 in mobile phase CE50 on a TLC plate pre-saturated with ammonia, detection with ninhydrin). The target product with the starting material was eluted with MeOH and this mixture was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (0-40 %). Carbamate ADA905028X was obtained as a colorless oil (1.7 g, 36% yield, Ay 0.8 in mobile phase D2, detection with ninhydrin). DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1832] HRMS (ESI): m / z calcd. for C23H49N2O2+[M + H]+385.3789; found 385.37878.

[1833] / c / 7-Butyl (5-( / V-dodecyl- / V-tridecylamino)pentyl)carbamate ADA905032X

[1834]

[0470] A 100 mL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of ADA905028X (0.85 g, 2.2 mmol) in MeCN: EtOAc 6:1 (v / v, 30 mL) and CHCh (20 mL). 1 -Bromododecane (0.79 mL, 3.3 mmol, 1.5 eq.) and anhydrous K2CO3 (3.05 g, 22.1 mmol, 10 eq.) were added and the reaction mixture was stirred at 55 °C for 3 nights. Progress of the reaction was monitored by TLC using a D3 mobile phase on a TLC (detection with ninhydrin). The reaction mixture was filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc and DCM. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (0-60 %). Carbamate ADA905032X was obtained as a yellowish oil (766 mg, 63% yield, Ay 0.6 in mobile phase D3, detection with ninhydrin).

[1835] HRMS (ESI): m / z calcd. for C35H73N2O2+[M + H]+553.5667; found 553.56708.

[1836] Ad-dodecyl- A1-tridecylpentane- 1,5 -diamine ADA905034X

[1837]

[0471] Boc-protected amine ADA905032X (766 mg, 1.4 mmol) was dissolved in DCM (5 mL) in a 50mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 3 hours. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted with EtOAc and NaHCOs in water. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCOs (300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine ADA905034X was obtained as a yellowish oil (513 mg, 82% yield, Ry 0.3 in mobile phase D2, detection with ninhydrin).

[1838] 'HNMR (600 MHz, CDCl3) 82.68 (t, J= 7.1 Hz, 2H), 2.39 (m, 6H), 1.53 (m, 1H), 1.44 (m, 9H), 1.26 (40), 0.87 (m, 6H). DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1839] 13C NMR(151 MHZ, CDCl3) 854.19, 54.13, 42.24, 33.86, 31.92, 29.69, 29.67, 29.66, 29.64, 29.35, 27.65, 26.90, 26.86, 24.90, 22.68, 14.11. HRMS (ESI): m / z calcd. for C30H65N2+[M + H]+453.5142; found 453.51418.

[1840] K2CO3MeCN / EtOAc

[1841] 55 °C ADA905028X CH3(CH2)iiCH2Br K2CO3MeCN / EtOAc / CHCI3

[1842] 55 °C CH3(CH2)i0CH2Br

[1843] HCI in 1,4-dioxane

[1844] DCM RT

[1845]

[1846] ADA905034X

[1847] Example 5 - ADA905036X

[1848] / c / V-Butyl (5-(hexadecylamino)pentyl)carbamate ADA905029X

[1849]

[0472] A lOOmL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of / c / V-butyl (5-aminopentyl)carbamate (1.27 g, 6.29 mmol) in MeCN: EtOAc 6:1 (v / v, 85 mL). 1 -Bromohexadecane (1.8 mL, 5.9 mmol, 0.95 eq.) and anhydrous K2CO3(8.54 g, 62.8 mmol, 10 eq.) were added and the reaction mixture was stirred at 55 °C for 3 nights and then at 70 °C overnight. Progress of the reaction was monitored by TLC using a D2 mobile phase (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (0- 35 %). Carbamate ADA905029X was obtained as a colorless oil (1.03 g, 39% yield, Ay 0.8 in mobile phase D2, detection with ninhydrin).

[1850] HRMS (ESI): m / z calcd. for C26H55N2O2+[M + H]+427.4258; found 427.42554.

[1851] / c / V-Butyl (5-(7V-hexadecyl-7V-octylamino)pentyl)carbamate ADA90503 IX DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1852]

[0473] A lOOmL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of ADA905029X (1.03 g, 2.4 mmol) in MeCN: EtOAc 6:1 (v / v, 50 mL) and DCM (20 mL). 1 -Bromooctane (0.63 mL, 3.6 mmol, 1.5 eq.) and anhydrous K2CO3(3.34 g, 24.1 mmol, 10 eq.) were added and the reaction mixture was stirred at 40 °C for 3 nights. Progress of the reaction was monitored by TLC using a D3 mobile phase on a TLC plate (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc and DCM. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %), some impurities were observed with TLC analysis. Impure fractions with product were adsorbed onto silica gel once more. Product was purified by flash chromatography with a gradient DI in DCM (0-20 %). Carbamate ADA905031X was obtained as a yellowish oil (486 mg, 37% yield, Ay 0.65 in mobile phase D3, detection with ninhydrin).

[1853] HRMS (ESI): m / z calcd. for C34H71N2O2+[M + H]+539.5510; found 539.55122.

[1854] / V1-hexadecyl- A1-octylpentane- 1,5 -diamine ADA905036X

[1855]

[0474] Boc-protected amine ADA905031X (486 mg, 0.902 mmol) was dissolved in DCM (5 mL) in a 50mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 10 minutes. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted between EtOAc and NaHCOi in water. The solution was then poured into a 500 mL separatory funnel, diluted with saturated aqueous NaHCOi (300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine ADA905036X was obtained as a yellowish oil (348 mg, 88% yield, Rf 0.4 in mobile phase D2, detection with ninhydrin).

[1856] 'H NMR (600 MHz, CDCl3) 82.68 (t, J= 7.1 Hz, 2H), 2.39 (m, 6H), 1.44 (m, 9H), 1.26 (m, 39H), 0.88 (m, 6H).

[1857] 13C NMR(151 MHZ, CDCl3) 854.20, 54.14, 42.26, 33.87, 31.92, 31.86, 29.70, 29.68, 29.67, 29.65, 29.64, 29.59, 29.36, 29.33, 27.66, 26.92, 26.88, 24.91, 22.69, 22.67, 14.12, 14.10. HRMS (ESI): m / z calculated for C29H63N2+[M + H]+439.4986; found 439.49852. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1858] O AIWlOW'JX Of i.N' N3, N '' () ■ MeCNI IOAL Sh T DIP! A (’. K: Ch W H Br diy DCM 40 C CK: CH::}CKBr

[1859] N ^ j NH. u'dtaane WI‘ U> ADA905031X

[1860]

[1861] ADA905036X RT

[1862] Example 6 - ADA905028X

[1863] / / 7-Butyl (5-(tridecylamino)pentyl)carbamate ADA905028X

[1864]

[0475] A 250mL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of tert-butyl (5-aminopentyl)carbamate (3.00 g, 14.8 mmol) in MeCN: EtOAc 6:1 (v / v, 170 mL). 1 -Bromotridecane (1.9 mL, 7.4 mmol, 0.5 eq.) and anhydrous K2CO3(20.5 g, 148 mmol, 10 eq.) were added and the reaction mixture was stirred at 55 °C for 3 nights. Progress of the reaction was monitored by TLC using a D3 mobile phase (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer, and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (0-33 %). Carbamate ADA905028X was obtained as a colorless oil (1.78 g, 62% yield, A / 0.2 in mobile phase D3, detection with ninhydrin).

[1865] HRMS (ESI): m / z calculated for C23H49O2N2+[M + H]+385.3789; found 385.37878.

[1866] tert-Butyl (5-(7V-tridecyl-7V-undecylamino)pentyl)carbamate ADA905033X

[1867]

[0476] A 250mL flask equipped with a magnetic stirring bar and a septum containing a needle outlet was charged with a solution of ADA905028X (1.00 g, 2.6 mmol) in MeCN: EtOAc 6:1 (v / v, 70 mL) and CHCI3 (20 mL). 1 -Bromoundecane (1.0 mL, 4.5 mmol, 1.7 eq.) and anhydrous K2CO3 DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1868] (3.05 g, 22.1 mmol, 8.5 eq.) were added and the reaction mixture was stirred at 55 °C overnight. Progress of the reaction was monitored by TLC using a D3 mobile phase on a TLC (detection with ninhydrin). Another portion of 1 -Bromoundecane (0.5 mL, 2.3 mmol, 0.85 eq.) was added and the reaction was stirred at 55 °C overnight again. The reaction mixture was then filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc and DCM. The filtrate was adsorbed onto silica gel and the product was purified by flash chromatography with a gradient of DI in DCM (2-20 %). Carbamate ADA905033X was obtained as a yellowish oil (928 mg, 66% yield, Ay 0.7 in mobile phase D3, detection with ninhydrin).

[1869] HRMS (ESI): m / z calculated for C34H71O2N2+[M + H]+539.5510; found 539.55120.

[1870] A1-tridecyl- A1-undecylpentane- 1,5 -diamine ADA905035X

[1871]

[0477] Boc-protected amine ADA905033X (928 mg, 1.72 mmol) was dissolved in DCM (5 mL) in a 50mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 20 minutes. The progress of the reaction was monitored by TLC using a D2 mobile phase. The sample for TLC analysis was extracted between EtOAc and NaHCO3in water. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO3(300 mL), and the crude product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and adsorbed onto silica gel. The crude product was purified by silica gel column chromatography using gradient of DI in DCM (0-75 %). Amine ADA905035X was obtained as a yellowish oil (672 mg, 88% yield, R / 0.4 in mobile phase D2, detection with ninhydrin).

[1872] 'HNMR (600 MHz, CDCl3) 82.68 (t, J= 7.1 Hz, 2H), 2.38 (m, 6H), 1.54 (m, 1H), 1.43 (m, 9H), 1.28 (m, 38H), 0.88 (m, 6H).

[1873] 13C NMR(151 MHZ, CDCl3) 854.19, 54.14, 42.25, 33.86, 31.91, 29.69, 29.67, 29.66, 29.64, 29.63, 29.35, 29.34, 27.65, 26.91, 26.87, 24.90, 22.68, 14.11. HRMS (ESI): m / z calculated for C29H63N2+[M + H]+439.4986; found 439.49846. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1874] O. M- Ch AOA90. W8X O H. N N1OH L i'-' 11 ’ Qi: cM, t CKIQUj. CH-Bf

[1875] CHs(CHjl3CH2Br 0,1',;t M- 1 - t; Nlf. 1 4-l'x",w"C' h‘N; N1‘ (>, • ■* - < \ IM.. M PT ADA305O > iX

[1876]

[1877] ADA905035X

[1878] Example 7 - ADA905073X

[1879] / / 7-Butyl (3-((didodecylamino)methyl)benzyl)carbamate ADA905066X

[1880]

[0478] A lOOmL flask equipped with a magnetic stirring cross-bar and a septum containing a needle outlet was charged with a solution of tert-butyl (3-(aminomethyl)benzyl)carbamate (1.00 g, 4.23 mmol) in MeCN: EtOAc 6:1 (v / v, 70 mL) and chloroform (20 mL).

[1881] 1 -Bromododecane (2.64 g, 10.6 mmol, 2.5 eq.) and anhydrous K2CO3(5.85 g, 42.3 mmol, 10 eq.) were added and the reaction mixture was stirred at 60 °C for 3 nights. Progress of the reaction was monitored by TLC using a 50:50 (v / v) CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified flash chromatography with a gradient of EtOAc in cyclohexane (0-80 %), fractions with the product were combined, solvents were removed under vacuum on a rotary vacuum evaporator and the crude product was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (2-8 %). Carbamate ADA905066X was obtained as a yellowish oil (0.47 g, 19.5% yield, A / 0.7 in mobile phase D20, detection with ninhydrin). Product was analyzed by UPLC-MS (HC / ESI): m / z calculated for C37H69N2O2+[M + H]+573.54; found 573.5. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1882] 3-((A, A-didodecylamino)methyl)benzylamine ADA905073X

[1883]

[0479] Boc-protected amine ADA905066X (0.47 g, 0.83 mmol) was dissolved in DCM (5 mL)in a 50mL round botom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 20 minutes. The progress of the reaction was monitored by TLC using a D3 mobile phase. The sample for TLC analysis was extracted between EtOAc and NaHCO3in water. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO3(300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of coton wool, and solvent was removed under vacuum on a rotary vacuum evaporator. Amine ADA905073X was obtained as a yellowish oil (0.35 g, 90% yield). Product was analyzed by UPLC-MS (TIC / ESI): m / z calculated for C32H61N2+[M + H]+473.48; found 473.4.

[1884] 'H NMR (600 MHz, CDCl3) 8 7.24 (m, 4H), 3.86 (s, 2H), 3.58 (s, 2H), 2.43 (m, 4H), 2.02 (br s, 2H), 1.45 (m, 4H), 1.28 (m, 36H), 0.88 (m, 6H).

[1885] 13C NMR (151 MHZ, CDCl3) 8 143.21, 139.6, 128.33, 127.71, 127.50, 125.62, 58.40, 53.65, 46.47, 31.91, 29.67, 29.64, 29.63, 29.54, 29.35, 27.43, 26.55, 22.68, 14.11.

[1886] ADA905066X C K. CO - — — - MoCN / f tCiAc.'CHl.l- bO C HOI in 1 I diet. mo DCM IH

[1887]

[1888] Example 8 - ADA905084X

[1889] tert-Butyl (6-(tridecylamino)hexyl)carbamate ADA905068X DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1890]

[0480] A 250mL flask equipped with a magnetic stirring cross-bar and a septum containing a needle connected to a ballon with argon was charged with a solution of tert-butyl (6- aminohexyl)carbamate (3.00 g, 13.9 mmol) in MeCN: EtOAc 6:1 (v / v, 170 mL). 1- Bromotridecane (1.8 mL, 7.0 mmol, 0.5 eq.) and anhydrous K2CO3(19.2 g, 139 mmol, 10 eq.) were added and the reaction mixture was stirred at 55 °C for 5 days. Progress of the reaction was monitored by TLC using a D3 mobile phase (detection with ninhydrin). The reaction mixture was filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc and DCM. The filtrate was adsorbed onto silica gel and purified flash chromatography with a gradient of DI in DCM (5-20 %). Carbamate ADA905068X was obtained as a white waxy solid (1.88 g, 68% yield, Ay 0.5 in mobile phase D3, detection with ninhydrin). Product was analyzed by UPLC-MS (TIC / ESI): m / z calculated for C24H51N2O2+[M + H]+399.39; found 399.1.

[1891] tert-Butyl (6-(A-undecyl-A-tridecylamino)hexyl)carbamate ADA905082X

[1892]

[0481] The reaction was carried out in a 20 ml vial equipped with a stirring bar and plastic cap. The secondary amine ADA905068X (1.22 g, 3.06 mmol) was dissolved in dry DCM (8.1 mL). DIPEA (1.6 mL, 9.18 mmol, 3.0 eq.) was added in one portion, and 1 -bromoundecane (1.0 mL, 4.6 mmol, 1.5 eq.) was added dropwise over one minute. The reaction was stirred at 40 °C for 3 nights. Progress of the reaction was monitored by TLC using a D3 mobile phase (detection with ninhydrin). Volatiles were removed under vacuum on a rotary vacuum evaporator, crude product was dissolved in DCM and product was adsorbed onto silica gel and purified by flash chromatography with a gradient of DI in DCM (0-25 %). The product ADA905082X was obtained as a colorless oil (757 mg, 45% yield, Rf 0.8 in mobile phase D3, detection with ninhydrin). Product was analyzed by UPLC-MS (TIC / ESI): m / z calculated for C35H73N2O2+[M + H]+553.57; found 553.5.

[1893] A1-undecyl- TV1-tri decylhexane- 1,6-diamine ADA905084X

[1894]

[0482] Boc-protected amine ADA905082X (0.757 g, 1.37 mmol) was dissolved in DCM (5 mL) in a 50mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 20 minutes. The progress of the reaction was monitored by TLC using a D3 mobile phase. The sample for TLC analysis was extracted between EtOAc and NaHCOs in water. The solution was then DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1895] poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO3(300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and solvent was removed under vacuum on a rotary vacuum evaporator. Amine ADA905084X was obtained as a yellowish oil (0.603 g, 97% yield). Product was analyzed by UPLC-MS (HC / ESI): m / z calculated for C30H65N2+[M + H]+453.51; found 453.4.

[1896] 'H NMR (600 MHz, CDCl3) 8 2.68 (t, J = 7.0 Hz, 2H), 2.44 (br s, 6H), 1.89 (br s, 2H), 1.44 (m, 8H), 1.29 (m, 38H), 0.87 (m, 6H).

[1897] 13C NMR (151 MHz, CDCl3) 853.96, 42.16, 33.76, 31.91, 31.90, 29.68, 29.66, 29.64, 29.62, 29.57, 29.35, 29.33, 27.58, 27.43, 26.81, 26.52, 22.68, 14.11.

[1898] Al O

[1899] H. N ‘ fLO Mt’C. N'f tOAc

[1900] (

[1901] DIP! A dry DCM

[1902] H. NH JXie "C■;rN t- N;

[1903] H, CS■ - li, (MJ

[1904]

[1905] ’ ’ 9

[1906] ADA905084XRTADA905082X

[1907] Example 9 - ADA905085X

[1908] tert-Butyl (6-(hexadecylamino)hexyl)carbamate ADA905067X

[1909]

[0483] A 250mL flask equipped with a magnetic stirring cross-bar and a septum containing a needle connected to a ballon with argon was charged with a solution of tert-butyl (6- aminohexyl) carbamate (3.00 g, 13.9 mmol) in MeCN: EtOAc 6:1 (v / v, 170 mL). 1- Bromohexadecane (2.2 mL, 7.0 mmol, 0.5 eq.) and anhydrous K2CO3(19.2 g, 139 mmol, 10 eq.) DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1910] were added, and the reaction mixture was stirred at 55 °C for 5 days. Progress of the reaction was monitored by TLC using a D3 mobile phase (detection with ninhydrin). The reaction mixture was then filtered through an S4 sintered glass with a celite layer and the residue was washed with EtOAc and DCM. The filtrate was adsorbed onto silica gel and purified flash chromatography with a gradient of DI in DCM (5-20 %). Carbamate ADA905067X was obtained as a white waxy solid (1.83 g, 60% yield, Rf 0.5 in mobile phase D3, detection with ninhydrin). Product was analyzed by UPLC-MS (TIC / ESI): m / z calculated for C27H57N2O2 [M + H]+441.44; found 441.4.

[1911] tert-Butyl (6-(A-hexadecyl-A-octylamino)hexyl)carbamate ADA905083X

[1912]

[0484] The reaction was carried out in a 20mL vial equipped with a stirring bar and plastic cap. The secondary amine ADA905067X (1.51 g, 3.40 mmol) was dissolved in dry DCM (10 mL). DIPEA (1.8 mL, 10.2 mmol, 3.0 eq.) was added in one portion and 1 -bromooctane (0.88 mL5.1 mmol, 1.5 eq.) was added dropwise over one minute. The reaction was stirred at 40 °C for 3 nights. Progress of the reaction was monitored by TLC using a D3 mobile phase (detection with ninhydrin). Volatiles were removed under vacuum on a rotary vacuum evaporator, the crude product was dissolved in DCM, adsorbed onto silica gel, and purified by flash chromatography with a gradient of DI in DCM (0-25 %). The product ADA905083X was obtained as a colorless oil (745 mg, 40% yield, Rf 0.8 in mobile phase D3, detection with ninhydrin). Product was analyzed by UPLC-MS (TIC / ESI): m / z calculated for C35H73N2O2+[M + H]+553.57; found 553.6.

[1913] A1-hexadecyl- A1-octylhexane- 1,6-diamine ADA905085X

[1914]

[0485] Boc-protected amine ADA905083X (0.745 g, 1.35 mmol) was dissolved in DCM (5 mL) in a 50 mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar and 4M HC1 in dioxane (5 mL) was added. The reaction mixture was stirred at room temperature for 20 minutes. The progress of the reaction was monitored by TLC using a D3 mobile phase. The sample for TLC analysis was extracted between EtOAc and NaHCOs in water. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCOs (300 mL), and the product was extracted with Et₂O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through a piece of cotton wool, and solvent was removed under vacuum on a rotary vacuum evaporator. Amine ADA905085X was obtained as a yellowish oil DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1915] (0.582 g, 95% yield). Product was analyzed by UPLC-MS (HC / ESI): m / z calculated for C30H65N2+[M + H]+453.51; found 453.5.

[1916] ’H NMR (600 MHz, CDCh) 82.68 (t, J = 7.0 Hz, 2H), 2.43 (m, 4H), 1.97 (br s, 2H), 1.85 (m, 8H), 1.33 (m, 2H), 1.26 (m, 38H), 0.87 (m, 6H).

[1917] 13C NMR (151 MHz, CDCh) 853.97, 53.94, 42.15, 33.75, 31.91, 31.83, 29.69, 29.66, 29.64, 29.63, 29.62, 29.57, 29.52, 29.35, 29.29, 27.59, 27.57, 27.49, 27.42, 26.81, 26.56, 26.48, 22.68, 22.65, 14.11, 14.09.

[1918] ADA90M67X 'J j MeCN-1 IDA:*" •' ' 14^0

[1919] 55:C CH,. CIH-.-XKBr Dll’! A dry DC M 40 ' C | Ch jOlA-OvBr O

[1920] *4,{N *■ - * 4 ‘ 1 4 ritoxanoH C% C11,r■* *1~—

[1921] ' (, DCA’ J

[1922] ■ ADA90508 1X

[1923]

[1924] ADA90b08!»X

[1925] Example 10 - ADA901749X

[1926] / / 7-Butyl (6-(didodecylamino)hexyl)carbamate ADA901746X

[1927]

[0486] A 500 mL round-botom flask equipped with a chlorcalcium cap and magnetic stirrer was charged with a solution of tert-butyl (6-aminohexyl)carbamate (4.00 g, 18.5 mmol) in MeCN (75 mL). 1 -Bromododecane (11.1 mL, 46.2 mmol, 2.5 eq.) and anhydrous K2CO3(25.6 g, 185 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 24 h. Progress of the reaction was monitored by TLC using a CE20 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was filtered through an S2 sintered glass with a celite layer, and the residue was washed with DCM. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA901746X was obtained as a DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1928] pale-yellow oil (7.46 g, 73% yield; Rf 0.4 in mobile phase CE5 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1929] / V1, / V1-Di dodecyl hexane- 1,6-diamine ADA901749X

[1930]

[0487] A solution of HC1 in dioxane (4M 8 mL) was added to a solution of Boc-protected amine ADA901746X (7.51 g, 13.6 mmol) inDCM (5 mL) in a 250mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar. The reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC using a D2 mobile phase. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO3(300 mL), and the product was extracted with Et2O (4 x 50 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through an S2 sintered glass, and adsorbed onto silica gel. The crude product was purified by flash chromatography on a silica gel column using gradient of DI in DCM (0-60 %). Amine ADA901749X was obtained as a pale yellow oil (5.65 g, 92% yield, Ay 0.5 in mobile phase D2, detection with ninhydrin).

[1931] 'H NMR (600 MHz, CDCl3) 8 2.73 (t, J = 7.1 Hz, 2H), 2.65 (m, 2H), 2.57 (m, 4H), 1.56 (m, 2H),1.52 (m, 4H), 1.51 (m, 2H), 1.36 (m, 2H), 1.31 (m, 2H), 1.27 (m, 36H), 0.87 (t, J= 7.1 Hz, 6H).

[1932] 13C NMR

[1933]

[1934] (151 MHZ, CDCl3) 853.51, 53.20, 41.62, 32.40, 31.89, 29.63, 29.61, 29.57, 29.44, 29.32, 27.39, 27.09, 26.53, 25.65, 25.02. 22.66, 14.10. IR (film): Vmax / crn’1= 3374 w and 3294 w (v NH2), 2797 m (vsN-CH2), 2956 s (vas CH3), 2924 vs (vasCH2), 2853 s (vsCH2), 1467 m and 1455 m, sh (psCH2and Sas CH3), 1378 w and 1367 w (8SCH3), 721 m (Pas CH2). HRMS (ESI): m / z calculated for C30H65N2[M + H]+453.51423; found 453.51340. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1935] K. (A). ADA901 / 4GX L I

[1936] H. N 1 \ is - Mt'C. N

[1937] 55:C CH. (CH h. HUHr HO in 1 4-dio»ane IJCM H I VN Nl i.

[1938]

[1939] ‘ | A? A9(H74i)X

[1940] Example 11 - ADA901770X

[1941] A- / c / 7-Buty I oxy carbonyl cystamine §ADA901765X

[1942]

[0488] Cystamine dihydrochloride (5.0 g, 32.84 mmol) was added to a solution of triethylamine (13.73 mL, 98.5 mmol, 3 eq.) in methanol (200 mL) in a 500mL round bottom flask. Then, a solution of BOC2O (7.17 mL, 32.84 mmol, 1 eq.) in methanol (100 mL) was added over 10 min and the reaction was stirred for 1 d at RT. The reaction mixture was evaporated to give a white residue, which was partitioned between aqueous citric acid (10 g of citric acid in 300 mL of H2O) and diethylether (2 x 100 mL) in a 1000 mL separatory funnel. The aqueous phase was subsequently alkalized by sodium hydroxide solution (2M, 100 mL), and the product was extracted with diethyl ether (2x 100 mL), dried over Na2SC>4, and evaporated. The combined organic phase was washed with brine (200 mL), dried over anhydrous sodium sulfate, and evaporated to give Boc-protected amine ADA901765X as a pale-yellow oil (1.963 g, 24% yield, Ry 0.5 in mobile phase D2, detection with ninhydrin).

[1943] / c / V-Butyl (6-(didodecylamino)-3,4-dithiohexyl)carbamate ADA901766X

[1944]

[0489] A 250 mL round bottom flask equipped with a magnetic stirring bar and a chlorocalcium cap was charged with a solution of amine ADA901765X (1.96 g, 7.77 mmol) in MeCN (75 mL). 1- Bromododecane (4.65 mL, 19.41 mmol, 2.5 eq.) and anhydrous K2CO3(10.73 g, 77.7 mmol, 10 DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1945] eq.) were added, and the reaction mixture was stirred at 55 °C for 3 d. Progress of the reaction was monitored by TLC using a CE20 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was filtered through an S2 sintered glass with a celite layer, and the residue was washed with EtOAc. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of EtOAc in cyclohexane (0-80 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA901766X was obtained as a colorless oil (2.55 g, 56% yield; Ay 0.5 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1946] / V1, / V1-didodecyl-3,4-dithiohexane- l,6-diamine ADA901770X

[1947]

[0490] A solution of HC1 in dioxane (4M, 10 mL) was added to a solution of Boc-protected amine ADA901766X (2.55 g, 4.33 mmol) inDCM (5 mL) in a 250mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar at 0 °C. The ice bath was removed and the reaction mixture was stirred at room temperature for 24 h. The progress of the reaction was monitored by TLC using D2 mobile phase. The solution was then poured into a 500mL separatory funnel, diluted with saturated aqueous NaHCO3(250 mL), and the product was extracted with Et2O (3 x 50 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered through an S2 sintered glass, and adsorbed onto silica gel. The crude product was purified by flash chromatography on silica gel column using gradient of DI in DCM (0-50 %). Amine ADA901770X was obtained as a pale-yellow oil (1.92 g, 91% yield; Ay 0.6 in mobile phase D2, detection with ninhydrin).

[1948] 'H NMR (600 MHz, CDCl3) 8 3.01 (t, J = 5.8 Hz, 2H), 2.79 (m, 4H), 2.77 (t, J = 5.9 Hz, 2H) 2.45 (m, 4H), 1.71 (br s, 2H), 1.44 (m, 4H), 1.27 (m, 36H), 0.89 (t, J= Hz, 6H).

[1949] 13C NMR(151 MHZ, CDCl3) 854.17, 53.50, 42.70, 40.63, 36.37, 31.91, 29.67, 29.64, 29.63, 29.58, 29.34, 27.47, 26.97, 22.68, 14.10. HRMS (ESI): m / z calcd. for C28H61N2S2 [M + H]+489.42707; found 489.42667. DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1950] Boc;C

[1951] H N.!?Ct H’'JHS\h ‘". I Ft. N IM'H P. T ADA901 ffifiX k?GC MAA

[1952] 55 -C CH.iCH u, CH. Br CH HCl ui ▼ I '11.4 dtoMiie - I AM

[1953] 0 C In Idh’C i, RADA90VZ0X

[1954]

[1955] Example 12 - ADA901786X

[1956] 3 -Methylhexyl 7-bromoheptanoate ADA901780X

[1957]

[0491] DIC (15.7mL, 102.6mmol, 1.3 eq.) and DMAP (289 mg, 2.37 mmol, 0.03 eq.) were added to a solution of 7-bromoheptanoic acid (16.5 g, 79.4 mmol) and 3-methylhexan-l-ol (12.26 mL, 86.8 mmol, 1.1 eq.) in DCM (200 mL), and the mixture was stirred overnight at RT. The reaction mixture was then adsorbed onto silica gel, and the solvents were evaporated under vacuum on a rotary vacuum evaporator. The crude product was purified by flash chromatography on silica gel (elution with a gradient of ethyl acetate in cyclohexane, 0-10 %) to yield the compound ADA901780X as a colorless oil (21.02 g, 87% yield; Rf 0.3 in CE5, visualization by KMnCL).

[1958] tert-Butyl (5-(di(((3-methylhexyl)oxycarbonyl)hexyl)amino)pentyl)carbamate ADA901783X

[1959]

[0492] A 40mL vial equipped with a magnetic stirring cross-bar and a septum cap containing a needle outlet was charged with a solution of tert-butyl (5-aminopentyl)carbamate (0.530 g, 2.62 mmol) in a mixture of MeCN (30 mL) and EtOAc (5 mL). Bromide ADA901780X (2.01 g, 6.55 mmol, 2.5 eq.) and anhydrous K2CO3(3.62 g, 26.2 mmol, 10 eq.) were added, and the reaction mixture was stirred at 55 °C for 45 h. Progress of the reaction was monitored by TLC using a CE50 mobile phase on a TLC plate pre-saturated with ammonia (detection with ninhydrin). The reaction mixture was filtered through an S2 sintered glass with a celite layer, and the residue was washed with DTS Ref.: 41089.BTL.P110PC December 19, 2025

[1960] DCM. The filtrate was adsorbed onto silica gel and purified by flash chromatography with a gradient of EtOAc in cyclohexane (0-60 %) on a silica gel column pre-saturated with gaseous ammonia. Carbamate ADA901783X was obtained as a colorless thick oil (1.34 g, 78% yield; Rf 0.7 in mobile phase CE50 on a TLC plate pre-saturated with ammonia, detection with ninhydrin).

[1961] N^N1-Di(((3-methylhexyl)oxycarbonyl)hexyl)pentane- 1,5 -diamine ADA901786X

[1962]

[0493] A solution of HC1 in dioxane (4M, 10 mL) was added to a solution of Boc-protected amine ADA901783X (1.34 g, 2.05 mmol) in DCM (5 mL) in a 250mL round bottom flask equipped with a plastic stopper and a magnetic stirring bar at 0 °C using an ice bath. The ice bath was then removed and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC using a D2 mobile phase. The solution was then poured into a 500 mL separatory funnel, diluted with saturated aqueous NaHCO3(300 mL), and the product was extracted with Et2O (2 x 100 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered through an S2 sintered glass, and adsorbed onto silica gel. The crude product was purified by flash chromatography on a silica gel column using gradient of DI in DCM (0-60 %). Amine ADA901786X was obtained as a pale-yellow oil (0.962 g, 85% yield; Ay 0.4 in mobile phase D2, detection with ninhydrin).

[1963] ADA901780X

[1964] DIV.: al DM / iP ► IX’ W RT kj Wvt. M ■? V...

Claims

DTS Ref.: 41089.BTL.P110PC December 19, 2025CLAIMS1. A compound of Formula I:whereinA1is -CH2- or a direct bond;A2is -CH2- or a direct bond;X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle comprising at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH- and -CH(OH)-;Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains or C4-C12 alkenylene chains or C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in the said alkylene chain, one or more -CH2-groups are optionally replaced with one or more O and / or S atoms and / or -N(R6)-;wherein R6are the same or different from each other, wherein each R6is selected from the group consisting of alkyl C1-C4;DTS Ref.: 41089.BTL.P110PC December 19, 2025R1is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-, and -S-, wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3;R2is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3;R3is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3;R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -S-Se-, -Se-Se-, -Se-S-, -S-S-S-, -S-Se-S-, -C(=O)NH-, -NHC(=O)-, -O-, -O-C(=O)NH-, -NHC(=O)O-, -OC(=O)O-, -CF2-, -CHF-and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or moreDTS Ref.: 41089.BTL.P110PC December 19, 2025> CH- groups are optionally replaced with > C(OH)- and wherein in said alkyl, alkenyl or alkynyl, a terminal -CH3 group is optionally replaced with -OH, -CH2F, -CHF2 or -CF3;wherein R1comprises at least 7 carbon atoms;and wherein if R3is C1-C4 alkyl then one hydrogen from the terminal -CH3 group is optionally substituted with Z1;and wherein if R2or R4is C1-C4 alkyl then one hydrogen from the terminal -CH3 group is optionally substituted with Z2;Z1and Z2are same or different from each other, wherein Z1and Z2are independently selected from the group consisting of -OH, -NH2, -C(=O)NH2, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, --C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,whereineach R5are same or different from each other, wherein each R5is selected from hydrogen and -CH3;each E are same or different from each other, wherein each E is selected from O and S atoms;n is an integer within the range of 1 to 5; andT1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, F, -C(=O)O(C1-C3alkyl),DTS Ref.: 41089.BTL.P110PC December 19, 2025-C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - -C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -CONHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-COO, -C(=O)O(CH2)2-O-P(=O)(O-)-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2, -NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,-N+(CH3)2-(CH2)3-SO3-, -N+(CH3)2-(CH2)2-C(=O)O-,wherein R5, E and n are as defined above;or pharmaceutically acceptable salts or solvates thereof.

2. A compound of claim 1, wherein the R1, comprises at least 8 carbon atoms, preferably at least 10 carbon atoms.

3. A compound according to any preceding claim, wherein the R1and R3are same and R2and R4are same and wherein R1is different from R2.

4. A compound according to claim 1 or 2, wherein the R1and R2are same and R3and R4are same and wherein R1is different from R3.

5. A compound according to claim 1 or 2, wherein R1, R2, R3and R4are the same.

6. A compound according to any preceding claim, wherein X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -DTS Ref.: 41089.BTL.P110PC December 19, 2025C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C=C-,-CH=CH-, a five-membered heterocycle having at least 2 nitrogen atoms, -CH2C(=O)NH-, -CH2C(=O)O-, -CH2C(=S)O-, -CH2C(=S)S-, -CH2C(=O)NHNH-, -N=CH-, -CH=N-, -NH-N=CH-, -CH=N-NH-, -C(=S)NH-, -NHC(=O)NH-, -NHC(=O)O-, -OC(=O)NH-, -OC(=S)NH-, -NHC(=S)O-, -C(=O)-, -NHC(=S)NH-, and -CH(OH)-.

7. A compound according to any preceding claim, wherein X1and X2are same or different from each other, wherein X1and X2are independently selected from the group consisting of -C(=O)NH-, -C(=O)O-, -C(=O)NHNH-, -NHC(=O)-, -C(=S)NH-, -OC(=O)NH-, -NHC(=O)O-, -NHC(=O)NH-8. A compound according to any preceding claim, wherein Y1and Y2are same of different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C12 alkylene chains, C4-C12 alkenylene chains, C4-C12 alkynylene chains and C8-C12 arylene comprising chains, wherein in said C2-C12 alkylene chain, one or more -CH2- groups are optionally replaced with one or more O, S atoms or -N(R6)-.

9. A compound according to any preceding claim, wherein Y1and Y2are same or different from each other, wherein Y1and Y2are independently selected from the group consisting of C2-C6 alkylenechains,, -CH2-CH2-S-S-CH2-CH2- and -CH2-CH2-O-CH2-CH2-.

10. A compound according to any preceding claim, wherein T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -OH, -CH3, -CH2OH, -NH2, -CN, -F, -C(=O)O(C1-C3alkyl), -C(=O)OCH2CH2OH, -C(=O)NH2, -C(=O)OH, -C(=O)NH(CH2)2OH, -C(=O)N[(CH2)2OH]2, - C(=O)NHCH(CH2OH)2, -C(=O)NHCH2CH(-OH)CH2OH, -C(=O)NH(CH2)2C(=O)NH2, -C(=O)N[CH2C(=O)NH2]2, -C(=O)NHCH[C(=O)NH2]2, -C(=O)NH(CH2)2NHC(=O)NH2, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)3-SO3, -C(=O)NH(CH2)3-N+(CH3)2-(CH2)2-C(=O)O, -C(=O)O(CH2)2-O-P(=O)(O )-O(CH2)2-N+(CH3)3, -O(C1-C3alkyl), -NH2, -NHC(=O)CH3, -NHS(=O)2CH3, -NHC(=O)N(CH3)2,DTS Ref.: 41089.BTL.P110PC December 19, 2025-NHC(=O)NH(CH3), -NHC(=S)N(CH3)2, -NHC(=S)NH(CH3), -NHC(=N-CN)NH2, -NHC(=N-CN)NH(CH3), -NHC(=N-CN)N(CH3)2, -NHC[=N-S(=O)2NH2]NH2,-N+(CH3)2-(CH2)3-SO3, -N+(CH3)2-(CH2)2-C(=O)O,wherein each R5are same or different from each other, and is selected from hydrogen and -CH3;each E are same or different from each other, wherein each E is from O and S atoms;and n is an integer within the range of 1 to 5.

11. A compound according to any preceding claim, wherein T1and T2are same or different from each other, wherein T1and T2are independently selected from the group consisting of -H, -CN, -F, -C(=O)NH2, and12. A compound according to any preceding claim, wherein R1, R2, R3or R4is selected from the group consisting of C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl, wherein said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl may be linear or branched, and wherein in said alkyl, alkenyl or alkynyl, one or more -CH2- groups are optionally replaced with one or more groups selected from the group consisting of -CH(OH)-, -OC(=O)-, -C(=O)O-, -S-S-, -C(=O)NH-, -NHC(=O)-, -O-, and -S-; wherein if said C1-C46 alkyl, C2-C46 alkenyl and C2-C46 alkynyl is branched, then one or more > CH- groups are optionally replaced with > C(OH)-.DTS Ref.: 41089.BTL.P110PC December 19, 202513. A compound according to any preceding claim, wherein R1or R2is selected from the group consisting of C8-C16alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups.

14. A compound according to any preceding claim, wherein R3is selected from the group consisting of C1-C16 alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in the said alkyl, terminal CH3 is optionally replaced with -OH.

15. A compound according to any preceding claim, wherein the compound is selected from the group consisting ofDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA905022LADA901801LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA901764LADA901745LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA901742LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 20250^ o -r \ 1 ' NH HN' 11KMM ADA901867LDTS Ref.: 41089.BTL.P110PC December 19, 2025NH HNOf\ 1 / ■ w UN\ ADA905040LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025s s'ADA901178LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025 o,: I* I NH UN / |j ' 'VsC ' Nb ADA901763L \ / X / X / X / \ZXzNxXX / XxX / XZXZ z'X / X / K^x^s / ^ N. ADA901797L V\ / XzXXX / ^Nx / ^DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005032LADA005008LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005013LADA005014LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005013LADA005014LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003023LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003021LADA003020LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003017LADA000012LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003033LADA005041L16. A compound according to any preceding claim, wherein R3is selected from the group consisting of C2-C16alkyl, wherein said alkyl is linear or branched, and wherein in the said alkyl, one or more -CH2groups are optionally replaced with one or more -C(=O)O- or -CH(OH)- groups and wherein in the said alkyl, a terminal -CH3is optionally replaced with -OH.DTS Ref.: 41089.BTL.P110PC December 19, 202517. A compound according to any preceding claim, wherein at least one of R1, R2, R3or R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- groups.

18. A compound according to any preceding claim, wherein at least two of R1, R2, R3or R4is selected from the group consisting of C8-C16alkyl, wherein said alkyl may be linear or branched, and wherein in the said alkyl, one or more -CH2- groups are optionally replaced with one or more -C(=O)O- groups.

19. A compound selected from the group consisting of:DTS Ref.: 41089.BTL.P110PC December 19, 2025ADA905022LADA901801LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA901764LADA901745LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA901742LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 20250^ o -r \ 1 ' NH HN' 11KMM ADA901867LDTS Ref.: 41089.BTL.P110PC December 19, 2025NH HNOf\ 1 / ■ w UN\ ADA905040LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025s s'ADA901178LDTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025 o,: I* I NH UN / |j ' 'VsC ' Nb ADA901763L \ / X / X / X / \ZXzNxXX / XxX / XZXZ z'X / X / K^x^s / ^ N. ADA901797L V\ / XzXXX / ^Nx / ^DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025DTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005032LADA005008LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005013LADA005014LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA005015LADA005039LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003023LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003021LADA003020LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003017LADA000012LDTS Ref.: 41089.BTL.P110PC December 19, 2025ADA003033LADA005041L20. A lipid composition comprising at least one compound of Formula I according to any preceding claim.

21. A lipid composition according to claim 20, wherein the lipid composition further comprises at least one helper lipid, wherein the at least one helper lipid is selected from the group comprising structural lipid, sterols and stabilizing agents.DTS Ref.: 41089.BTL.P110PC December 19, 202522. A lipid composition according to claim 21, wherein the structural lipid is selected from the group comprising l,2-dioleoyl-s77-glycero-3-phosphoethanolamine (DOPE),l-stearoyl-2-oleoyl-sn-glycero-3 -phosphoethanolamine (SOPE),1 -palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE),1.2-dioleoyl-sn-gly cero-3 -phosphocholine (DOPC),1.2-distearoyl-5 / 7-glycero-3-phosphocholine (DSPC),1.2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),1.2-dimyristoyl-s7?-glycero-3-phosphocholine (DMPC), and1.2-dioleoyl-577-gly cero-3- phosphoethanolamine-A-(Cyanine 5),1.2-dioleoyl-3 -dimethylammonium-propane (DOD AP),1.2-dioleoyl-3-trimethylammonium-propane (DOTAP),1.2-dilinoleoyl-sn-gly cero-3 -phosphocholine (DLPC),1.2-dioleoyl-sn-gly cero-3 -phosphocholine (DOPC),1.2-diundecanoyl-s77-glycero-phosphocholine (DUPC),1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),1.2-di-O-octadecenyl-577-glycero-3-phosphocholine (18:0 diether PC),l-oleoyl-2-cholesterylhemisuccinoyl-577-glycero-3-phosphocholine (OChemsPC),l-hexadecyl-s77-glycero-3 -phosphocholine (CI 6 Lyso PC),1,2-dilinolenoyl-sn-glycero-3-phosphocholine,1.2-diarachidonoyl-577-glycero-3-phosphocholine,1.2-didocosahexaenoyl-577-glycero-3-phosphocholine,1.2-diphytanoyl-s77-glycero-3-phosphoethanolamine (ME 16.0 PE),1.2-distearoyl-s77-glycero-3-phosphoethanolamine,1.2-dilinoleoyl-577-glycero-3-phosphoethanolamine,1.2-dilinolenoyl-577-glycero-3-phosphoethanolamine,1.2-diarachidonoyl-s77-glycero-3-phosphoethanolamine,1.2-didocosahexaenoyl-577-glycero-3-phosphoethanolamine,1.2-dioleoyl-5 / 7-glycero-3-phospho-rac-(l-glycerol) sodium salt (DOPG), diphytanoylphosphatidylcholine (DPhPC), dioleoy 1-3 -trimethylammonium propane (DO AB), dierucoylphosphatidylcholine (DEPC), dilinoleoylphosphatidylcholine (DEPC) and sphingomyelin.DTS Ref.: 41089.BTL.P110PC December 19, 202523. A lipid composition according to claim 21, wherein the sterol is selected from the group comprising cholesterol, β-sitosterol, stigmastanol, campesterol, fucosterol, avenasterol, fecosterol, brassicasterol, ergosterol, coprostanol and 9, 11 -dehydroergosterol.

24. A lipid composition according to claim 21, wherein the stabilizing agent is selected from the group comprising poly(ethyleneglycol), poly(2-ethyl-2-oxazoline), poly(2-methyl-2-oxazoline), poly(glycerol), poly(N- (2-hydroxypropyl) methacrylamide), poly (sarcosine) or glycol chitosan, 1,2-dimyristoyl-rac-glycero-3-methoxypoly(ethyleneglycol)-2000,1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000(DMG-PEG2000),1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000 and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-poly(ethyleneglycol)-2000.

25. A lipid composition according to any one of claims 21 to 24, wherein the compound of Formula I is in the range of 2.5 to 80 mol %, the structural lipid is in the range of 2.5 to 50 mol %, the sterol is in the range of 2.5 to 80 mol % and the stabilizing agent is in the range of 0.1 to 80 mol %.

26. A lipid composition according to any one of claims 21 to 25, wherein the compound of Formula I is in the range of 30 to 50 mol %, the structural lipid is in the range of 10 to 29 mol %, the sterol is in the range of 37.5 to 43.5 mol % and the stabilizing agent is in the range of 1.2 to 1.8 mol %.

27. A lipid composition according to any one of claims 21 to 26, wherein the lipid composition comprises 33 mol % of compound of Formula I, 27 mol % of at least one structural lipid, 38.5 mol % of at least one sterol and 1.5 mol % of at least one stabilizing agent.

28. A lipid composition according to any one of claims 21 to 27, wherein the lipid composition comprises 33 mol % of compound of Formula I, 27 mol % of DOPE, 38.5 mol % of cholesterol and 1.5 mol % of DMG-PEG2000.

29. A lipid composition according to claim 20, wherein the lipid composition further comprises at least one payload.

30. A lipid composition according to claim 29, wherein the payload is selected from the group comprising therapeutic agents and nucleic acids.DTS Ref.: 41089.BTL.P110PC December 19, 202531. A lipid composition according to claim 30, wherein the nucleic acid is selected from the group comprising ribonucleic acid (RNA), deoxyribonucleic acid (DNA), antisense oligonucleotides or peptide nucleic acid (PNA), single-stranded DNA, double-stranded DNA, cDNA, plasmid DNA, messenger RNA (mRNA), transfer RNA (tRNA), small interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA), piwi-RNA (piRNA), antisense RNA (asRNA) and guide RNA (gRNA).

Images